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Abstract
β-cell replacement therapy is potentially a curative approach in treating diabetes, as demonstrated by the
success of pancreatic islet transplantation in type 1 diabetes. However, there are an insufficient number
of organ donors to meet the demand of this disease, which is increasing in prevalence. One strategy to
increase the supply of human β-cells for transplantation in type 1 diabetics, or to increase residual β-cell
mass in type 2 diabetics, is to induce human β-cell replication. This strategy has not been implemented
clinically because adult human β-cells are largely quiescent and the capacity for proliferation decreases
with age. I hypothesized that changes in DNA methylation contribute to the age-related decline in
proliferative capacity in human β-cells, and that altering the DNA methylome in a targeted manner could
improve proliferative capacity. To investigate this hypothesis, I sought to profile the β-cell across the
human lifespan, and to develop tools that permit targeted DNA methylation modifications and efficiency
in measuring DNA methylation. I conducted RNA-Seq and whole-genome bisulfite sequencing (WGBS) to
profile the aging human β-cell transcriptome and DNA methylome. I found that there are significant
changes in gene expression with age, and in DNA methylation, particularly at islet-specific active
enhancers. Further, I developed transcription activator-like effector (TALE) fusion proteins conjugated to
DNA methyltransferases (DNMTs) and demonstrated that targeting TALE-DNMTs to the promoter of the
CDKN2A locus, encoding the cell cycle inhibitor p16, increases proliferation in primary human fibroblasts.
Finally, I developed BisPCR2, a novel technique for preparing targeted bisulfite next-generation
sequencing libraries, which greatly improves the efficiency in which DNA methylation can be measured at
target regions. I demonstrated the utility of this tool to validate genome-wide findings of type 2 diabetes
CpG risk loci. Together, these novel datasets and epigenetic tools poise the β-cell regeneration field to
investigate targeted epigenetic modifications as a strategy to improve proliferative capacity of adult
human β-cells.
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ABSTRACT
Targeted epigenetic editing to increase adult pancreatic β-cell proliferation
Diana L. Bernstein
Supervisor of Dissertation: Klaus Kaestner, Ph.D., M.S.
β-cell replacement therapy is potentially a curative approach in treating diabetes, as
demonstrated by the success of pancreatic islet transplantation in type 1 diabetes. However,
there are an insufficient number of organ donors to meet the demand of this disease, which is
increasing in prevalence.

One strategy to increase the supply of human β-cells for

transplantation in type 1 diabetics, or to increase residual β-cell mass in type 2 diabetics, is to
induce human β-cell replication. This strategy has not been implemented clinically because adult
human β-cells are largely quiescent and the capacity for proliferation decreases with age. I
hypothesized that changes in DNA methylation contribute to the age-related decline in
proliferative capacity in human β-cells, and that altering the DNA methylome in a targeted manner
could improve proliferative capacity. To investigate this hypothesis, I sought to profile the β-cell
across the human lifespan, and to develop tools that permit targeted DNA methylation
modifications and efficiency in measuring DNA methylation. I conducted RNA-Seq and wholegenome bisulfite sequencing (WGBS) to profile the aging human β-cell transcriptome and DNA
methylome. I found that there are significant changes in gene expression with age, and in DNA
methylation, particularly at islet-specific active enhancers.

Further, I developed transcription

activator-like effector (TALE) fusion proteins conjugated to DNA methyltransferases (DNMTs) and
demonstrated that targeting TALE-DNMTs to the promoter of the CDKN2A locus, encoding the
cell cycle inhibitor p16, increases proliferation in primary human fibroblasts. Finally, I developed
2

BisPCR , a novel technique for preparing targeted bisulfite next-generation sequencing libraries,
which greatly improves the efficiency in which DNA methylation can be measured at target
regions. I demonstrated the utility of this tool to validate genome-wide findings of type 2 diabetes
CpG risk loci. Together, these novel datasets and epigenetic tools poise the β-cell regeneration
field to investigate targeted epigenetic modifications as a strategy to improve proliferative
capacity of adult human β-cells.
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β-cell replacement therapy for diabetes mellitus
Human islet physiology & β-cell function
The pancreas is a dual function organ composed of both exocrine and endocrine glands
(Chandra and Liddle 2013). The exocrine portion of the pancreas supports digestion by secreting
pancreatic juices with digestive enzymes into the small intestine. The endocrine portion of the
pancreas, the Islets of Langerhans, is a nutrient sensing organ that is critical in the maintenance
of glucose homeostasis by secreting hormones in response to changing blood glucose levels.
Pancreatic islets are vascularized spheroid clusters of endocrine cells scattered throughout the
pancreas comprising only about 1% of the pancreas by mass. They are composed of several
main cell types including α-, β-, δ- and PP-cells, which work in concert to regulate blood glucose
(Vetere et al. 2014). β-cells secrete insulin in response to elevated blood glucose to promote
glucose uptake in peripheral tissues such as muscle, liver and adipose tissue, while suppressing
hepatic glucose output. α-cells fulfill the opposing function by secreting glucagon during periods
of low blood glucose to mobilize alternative fuel sources, primarily by stimulating hepatic
glycogenolysis and gluconeogenesis.

δ-cells secrete somatostatin to suppress hormone

secretion of neighboring α- and β-cells to fine-tune the glucose response (Hauge-Evans et al.
2009). Finally, PP-cells secrete pancreatic polypeptide, which plays a role in regulating food
intake (Batterham et al. 2003). The β-cell is of particular interest because β-cell dysfunction is at
the core of the pathogenesis of diabetes mellitus, a group of metabolic diseases affecting over
347 million patients world-wide (Wang et al. 2015c).
Pancreatic β-cells are the sole source of insulin in the body, and insulin secretion is
stimulated by high blood glucose levels. In the fed state, when glucose levels are high, glucose
crosses the cell membrane through facilitated diffusion mediated by GLUT1 transporters in
humans, and GLUT2 transporters in mouse (Devos et al. 1995; McCulloch et al. 2011). Once
inside the cell, glucose enters glycolysis, raising intracellular ATP concentrations and thereby the
ATP:ADP ratio. Glucokinase (GK) converts glucose to glucose-6-phosphate and is the ratelimiting enzyme in this process, acting as the glucose sensor.
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In fact, mutations in or

overexpression of GK alters the set-point for glucose-stimulated insulin secretion (Osbak et al.
2009). The increase in ATP results in closure of ATP-sensitive K+ channels (KATP), causing
membrane depolarization and opening of voltage-gated Ca

2+

channels and Ca

2+

influx. Ca

2+

influx is the penultimate step in insulin secretion, mediating fusion of insulin vesicles with the
plasma membrane and secretion of insulin into the surrounding vasculature (Prentki et al. 2013).
The ability of the β-cell, in concert with other islet endocrine cells, to regulate glucose
homeostasis at the organismal level depends upon maintenance of sufficient functional β-cell
mass, meaning both adequate β-cell number and glucose responsiveness. β-cell mass is
maintained by a balance between β-cell renewal and apoptosis. If functional β-cell mass is not
maintained, persistent elevation of blood glucose can have severe pathophysiological
consequences.

Diabetes mellitus
Diabetes mellitus is a group of metabolic disorders characterized by loss of functional
pancreatic β-cell mass leading to impaired glucose homeostasis, which manifests primarily as
hyperglycemia. The two main forms of this disease are type 1 and type 2 diabetes. Type 1
diabetes usually presents early in life and is a consequence of autoimmune destruction of β-cells.
Type 2 diabetes is an age-associated disorder in which peripheral insulin resistance leads to βcell exhaustion and ultimately β-cell death or dysfunction. Type 1 diabetes accounts for only
about 5% of all cases while type 2 diabetes accounts for the remaining 95% (Vetere et al. 2014).
Of increasing recognition are another set of disorders collectively known as maturity onset
diabetes of the young (MODY), which are monogenic disorders caused by disruption of genes
critical to β-cell function.

In total, MODY cases constitute between 2-5% of diabetes (Giuffrida

and Reis 2005).
All type 1 diabetes patients, and a subset of patients with other forms of diabetes, depend
on exogenous insulin (Vetere et al. 2014). While insulin replacement therapy and prescription
medications are widely used to manage metabolic consequences of diabetes, none recapitulate
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the precise and dynamic regulation of blood glucose by the β-cell. Consequently, patients face
considerable complications of abnormal glucose homeostasis including coronary artery disease,
neuropathy, nephropathy, retinopathy, and peripheral vascular disease, and are at increased risk
of adverse hypoglycemic events (McCall and Shapiro 2014; Roglic and Unwin 2010). Thus,
strategies aimed at replacing lost β-cells have emerged as an intense area of focus in the
diabetes research community.

β-cell replacement therapy
The success of β-cell replacement therapy has been demonstrated convincingly in
pancreatic islet transplantation, which has been shown to restore euglycemia in type 1 diabetics
(McCall and Shapiro 2014). In this procedure, human islets are isolated from deceased organ
donors and injected into the portal vein of the patient taking up residence in the liver. While the
therapeutic benefit of islet transplantation is undisputed, poor graft survival and complications
associated with chronic immunosuppression initially limited its implementation, and are ongoing
areas of research. The first attempts at islet transplantation can be traced back to as early as
1893, although the field truly gained momentum only in the year 2000 with publication of the
revolutionary “Edmonton Protocol”

(McCall and Shapiro 2014).

This protocol specified

immediate transplantation of isolated islets under a glucocorticoid-free immunosuppression
regimen (Shapiro et al. 2000). Sufficient mass for transplantation was defined as greater than
10,000 islet equivalents per kg recipient body weight.

All seven patients in this initial study

achieved insulin independence following transplantation. Building upon the “Edmonton Protocol,”
pancreatic islet transplantation has shown to provide superior glycemic control, reduced
hypoglycemic events, reduced secondary complications, and improved quality of life metrics in
comparison to pharmaceutical treatments alone (Ryan et al. 2005; Cure et al. 2008; Poggioli et al.
2006; Toso et al. 2007; McCall and Shapiro 2014; Rickels et al. 2013; Rickels et al. 2015).
Despite these successes, this procedure cannot be applied widely in large part due to
lack of organ donors. As demand for islet transplantation increases, it is estimated that only

4	
  
	
  

4,000 pancreata are available in the United States each year, with just a fraction of those in
condition for islet transplantation. Patients also frequently require islets from more than one
donor, limiting the supply even further (Halban et al. 2010; Johnson and Jones 2012).
Additionally, the islet grafts often survive for only 5 years, meaning patients may require multiple
transplantations.

The successes and challenges of islet transplantation have thus ignited

research efforts towards finding alternative sources of β-cells for replacement therapy. These
alternative sources include induced replication of pre-existing β-cells, transdifferentiation from
other cell types, and differentiation of β-cell either from embryonic stem cells (ESCs) or induced
pluripotent stem cells (iPSCs). Induction of replication of pre-existing β-cells is a particularly
attractive option since it has the greatest likelihood of maintaining β-cell identity. However, this
strategy has not been implemented so far because adult human β-cells are largely quiescent, and
proliferative capacity decreases in an age-dependent manner (Reers et al. 2009; De Tata 2014).
The islet transplantation setting to treat type 1 diabetes offers a unique opportunity
because islet cells can be manipulated ex vivo prior to transplantation to optimize β-cell
proliferation, function and survival.

For example, co-expression of growth factors and

antiapoptotic genes, or expression of shRNAs targeting pro-apoptotic genes, in human islets prior
to transplantation into non-obese diabetic severe combined immunodeficient (NOD-SCID) mice
has shown to improve graft performance and survival (Mahato 2009). One of the field’s current
goals is to identify genes that promote β-cell proliferation. Once the appropriate targets are
identified, the same principles could be employed to treat type 2 diabetes to expand residual βcell mass in these patients. The advantage of treating endogenous β-cells is that patients are not
subject to challenges with immunosuppression and graft survival.

On the other hand,

therapeutics must be suitable for systemic delivery, and target the β-cell specifically to minimize
off-target effects, particularly because the other extreme of proliferation and enhanced survival is
cancer. Understanding what might drive human β-cell proliferation and survival has the potential
to improve treatments for both type 1 and type 2 diabetes.
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Replication of pre-existing β-cells for replacement therapy
Establishment and maintenance of human β-cell mass
While comparatively little is known about human pancreas development relative to model
organisms, a few key studies have begun to provide insight into how and when β-cell mass is
established (Jennings et al. 2015).

During human development, pancreatic progenitors are

derived from the foregut endoderm, and endocrine progenitors are further specified by
neurogenin 3 (NEUROG3), which increases rapidly following the embryonic period, approximately
8 weeks post-conception. This spike in NEUROG3 is concurrent with the appearance of β-cells,
the first of the endocrine cells to differentiate in the human fetus. By 10 weeks post-conception,
clusters of β-cells are well-vascularized, and islets with complete complements of endocrine cells
are present at 12-13 weeks post-conception.

Following β-cell differentiation, proliferation of

precursor cells drops off dramatically, suggesting that after this point additional fetal β-cells are
derived from self-duplication rather than neogenesis (Jennings et al. 2015).
β-cell proliferation rates across the human lifespan have been gathered primarily through
histological analysis of pancreas autopsy specimens in a limited number of studies. It has been
found that after birth, a neonatal burst of β-cell proliferation leads to a doubling of β-cell mass by
5 years of age (Meier et al. 2008). A more recent study determined that this neonatal burst
occurs primarily in the first two years of life, with lower levels of proliferation persisting throughout
childhood (Gregg et al. 2012). By co-staining of insulin and Ki67 (a marker of cell proliferation) in
pancreatic sections ranging in age from 24 weeks premature to 74 years old, Gregg and
colleagues observed that at most, only 2% of β-cells are proliferating at any given time, and this
number drops off precipitously after early childhood to nearly undetectable numbers (Figure 1.1).
Further, Perl and colleagues measured thymidine analog incorporation in autopsy specimens
from cancer patients who received either iododeoxyuridine (IdU) or bromodeoxyuridine (BrdU)
therapy. They observed proliferating β-cells in patients up to 20 years old, but not in patients
over 30 years old, and by radiocarbon dating found that β-cells were very long-lived (Perl et al.
2010).

This study suggests that basal β-cell proliferation is diminished within the first three
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decades of life. Similarly, Cnop and colleagues confirmed that human β-cells are very long-lived
and that β-cell mass is established by approximately 20 years of age by measuring intracellular
lipofuscin body (LB) accumulation as a marker for aging (Cnop et al. 2010).

Another study

assessing pancreas donor samples ranging from 7 to 66 years old reported an age-dependent
decline in proliferation, although proliferating cells were detected in all samples, regardless of age
(Reers et al. 2009).
Considering a peak proliferation rate of 2%, β-cells are somewhat unique in this regards
as other neonatal tissues including liver, intestinal crypts, bone marrow and spleen, expand much
more rapidly in the same timeframe (Wang et al. 2015c). Even the pancreas itself expands from
approximately 3-5g at birth to on average 90g by adulthood (Crelin 1973; Innes and Carey 1994).
In summary, β-cell mass is established very early in life, and adult human β-cells are largely postmitotic.
Amongst these observational studies of autopsy specimens, there is considerable
variability in the reported rates of human β-cell proliferation, and a recent study calls into question
the use of Ki67 as a proliferative marker in these particular specimens in attempt to reconcile
such differences.

Sullivan and colleagues hypothesized that human autopsy and cadaver

donation conditions result in decreased proliferative markers depending on storage and treatment
of specimens (Sullivan et al. 2015). In this study, young murine and porcine pancreata were
exposed to warm ischemia followed by cold ischemia to mimic human autopsy conditions, in
comparison to immediate fixation, typically employed in animal models, and then Ki67 and PCNA
were assessed by immunofluorescence.

Exposure to autopsy-like conditions resulted in

decreased Ki67 and PCNA staining in β-cells, and a similar decay in Ki67 staining was also
observed in acinar cells (Sullivan et al. 2015). Thus, the precise landscape of human β-cell
proliferation with age is still incomplete, and sample collection conditions need to be optimized.
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Cell cycle regulation of human β-cells
Many mitogenic signaling pathways have been implicated in the regulation of β-cell
proliferation, all of which ultimately converge upon the core cell cycle machinery.

In rodent

models, many of the intermediate signaling pathways have been described, including insulin
receptor substrate/phosphatidylinositol-3 kinase/Akt (IRS-PI3K-Akt), glycogen synthase kinsase-3
(GSK3), protein kinase Cζ (PKCζ) pathways, among others, although the corresponding
pathways in human β-cells have not yet been mapped. These studies are reviewed in detail
elsewhere (Kulkarni et al. 2012; Bernal-Mizrachi et al. 2014; Stewart et al. 2015).
The cell cycle, defined as the period of time between subsequent rounds of DNA
replication and cell division, can be divided into four sequential phases, G1, S, G2, and M. DNA
replication, or synthesis, occurs during S-phase, and cellular division, or mitosis, occurs during Mphase. G1 and G2 are growth phases that precede S- and M- phases, respectively. The cell
cycle is punctuated by several checkpoints to ensure that the cellular environment is suitable for
further progression, and to check the integrity of the genome.

During G1, if environmental

conditions are not favorable, the cell can transition into a period of cell cycle arrest, or G0, where
it may remain indefinitely. While each checkpoint is critical to cell cycle progression, a strong
body of evidence has demonstrated that the G1/S checkpoint is particularly critical for regulating
mammalian β-cell proliferation (Tarabra et al. 2012).
Central to the G1/S checkpoint is the retinoblastoma (Rb) pathway. The Rb family of
“pocket” proteins restrain cell cycle progression at the G1/S checkpoint by sequestering E2F
transcription factors, which regulate expression of key cell cycle genes such as the A- and Ecyclins (Sherr and Roberts 1999). Phosphorylation of the Rb proteins by cyclin-dependent
kinases (CDKs) disrupts the E2F/Rb interaction, permitting cell cycle progression. CDK4 and
CDK6, stimulated by D-cyclins, are active early in G1, and CDK2, stimulated by E-cyclins, is
active later in G1. The CDK/cyclin complexes are negatively regulated by CDK inhibitors (CKIs),
belonging to either the INK4 (p16

INK4a

, p15

INK4b

, p18
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INK4c

, p19

INK4d

) or Cip/Kip (p21

Cip1

, p27

Kip1

,

p57

Kip2

) families. p16, which specifically inhibits CDK4 and CDK6, is of particular relevance in

mammalian β-cell proliferation (Salas et al. 2014).
Studies profiling G1/S cell cycle regulators at the protein level demonstrate that with the
exception of cyclin D2, all such proteins are present in the human β-cell (Fiaschi-Taesch et al.
2013a). Interestingly, a study of 164 human cadaveric islet samples showed that the majority of
the G1/S cell cycle regulators are localized to the cytoplasmic compartment, contrary to
expectations. Certain cell cycle inhibitors including Rb, p57, and sometimes p21, were nuclear.
All but five samples were from donors over the age of 20, and thus this study does not provide
insight into any potential age-related differences (Fiaschi-Taesch et al. 2013a). A follow-up study
showed that over-expression of CDK6 and cyclin D3 led to altered subcellular localization of G1/S
regulators and increased cell cycle entry of human β-cells (Fiaschi-Taesch et al. 2013b). These
findings are particularly interesting because although cell cycle regulators are often regulated at
the level of protein stability, certain regulators, such as p16, encoded by the CDKN2A locus, are
known to increase dramatically in expression in an age-related manner, suggesting a concurrent
role for transcriptional regulation (Wang et al. 2015c).
The balance between drivers of cell cycle progression, namely cyclins and CDKs, and
inhibitors of cell cycle progression, namely the CKIs, determines cell cycle progression. Efforts to
overcome this checkpoint inhibition in β-cells have included pushing the cell cycle forward by
overexpressing cyclins and CDKs, or by releasing the “brakes” by removing CKI’s. In rodent
models, both of these strategies have been successfully implemented, reviewed in detail
elsewhere (Cozar-Castellano et al. 2006). Some success has also been achieved in human βcells through over expression of cell cycle activators.

Takane and colleagues reported a

reversible 20-fold increase in human β-cell proliferation with doxycycline-induced over expression
of CDK6 and cyclin D1 (Takane et al. 2012). The same group has reported increases in human
β-cell proliferation by over-expressing CDK6 alone, as well as CDK4 in combination with cyclin
D1 (Fiaschi-Taesch et al. 2010; Cozar-Castellano et al. 2004).
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Suppression of cell cycle inhibitors has also been shown to increase human β-cell
proliferation in a few key studies. For instance, shRNA-mediated suppression of p57, which
inhibits multiple cyclin/CDK complexes, was shown to increase human β-cell proliferation by 3fold following the transplantation of islets in to the hyperglycemic environment of diabetic NODSCID mice (Avrahami et al. 2014). Tamaki and colleagues further corroborated the importance of
the Rb pathway by targeting multiple members of the Rb and p53 pathways by siRNA in human
islets in culture. siRNAs were delivered by electroporation of intact human islets and resulted in
increased proliferation of up to 10% as measured by 5-ethynyl-2’-deoxyuridine (EdU)
incorporation (Tamaki et al. 2014). In this study, p16 was not independently assessed, and
whether or not suppression of p16 is sufficient to restore proliferative capacity in human β-cells
has yet to be determined. Some points of caution when manipulating cell cycle regulators include
potential oncogenic activation, cell cycle re-entry without completion, and limited functionality of
newly replicated β-cells (Rieck et al. 2012).

β-cell mass plasticity in response to increased metabolic demand
Although β-cell mass is established prior to adulthood, it can reversibly expand in
response to instances of increased metabolic demand such as in pregnancy and obesity, at least
in rodents, and failure to do so can result in gestational diabetes or type 2 diabetes, respectively
(Rieck and Kaestner 2010; Tarabra et al. 2012). The fact that only certain individuals are
susceptible to disease under these circumstances suggests a genetic underpinning, which is also
of interest to the β-cell regeneration field (Tarabra et al. 2012).

Plasticity of β-cell mass in

response to increased demand for insulin has been investigated more thoroughly in rodent
models than in humans, and the limited number of human studies suggest that the response in
rodents is more robust. For instance, one murine model of obesity, the liver specific insulin
receptor knockout (LIRKO) mouse, shows a 30-fold increase in β-cell mass as a compensatory
response to ambient insulin resistance (Okada et al. 2007; Michael et al. 2000). However, the
degree of β-cell mass expansion depends on the particular model system. The C57Bl/6 mouse
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strain, for instance, shows a more modest increase in β-cell mass of 2.2-fold when obesity is
induced by high-fat diet (Sone and Kagawa 2005).
On the other hand, based on assessment of autopsy specimens, obese non-diabetic
individuals exhibited a 50% increase in β-cell volume in comparison to lean non-diabetic
individuals (Butler et al. 2003). This increase in β-cell volume was determined to be due to an
increase in β-cell number rather than size, and thought to result from neogenesis as measured by
counting insulin positive duct cells. These findings are interesting because other studies have
reported that the primary source of new β-cells is pre-existing β-cells in both humans and rodents
(Meier et al. 2008; Dor et al. 2004; Georgia and Bhushan 2004). In comparison, obese type 2
diabetics showed a 63% decrease in β-cell mass relative to non-diabetic obese counterparts,
which was attributed to apoptosis (Butler et al. 2003).

Other studies have reported similar

increases in β-cell mass of 30-40% in obese non-diabetic human subjects (De Tata 2014).
In rodent pregnancy models, β-cell mass increases from two- to five-fold, and levels
return to normal within ten days postpartum as a result of increased apoptosis, decreased
proliferation, and decreased β-cell size (Scaglia et al. 1995; Parsons et al. 1995). Some human
studies have reported slightly lower increases in β-cell mass in pregnant women compared to
non-pregnant women ranging from 1.4- to 2.4-fold (Butler et al. 2010; Vanassche et al. 1978).
Interestingly, Butler and colleagues found the primary mechanism of β-cell expansion during
human pregnancy was neogenesis compared to the replication-driven β-cell mass expansion well
documented in rodents (Butler et al. 2010; Parsons et al. 1992; Rieck et al. 2009). During
pregnancy, increased β-cell mass is mediated by hormones including placental lactogen,
prolactin, growth hormone, and serotonin, and downstream signaling events are being explored in
rodent models (Rieck and Kaestner 2010; Tarabra et al. 2012). Importantly, these responses to
increased metabolic demand indicate that adult β-cell mass can expand, although the variation in
observed responses, the lack of consensus on the origin of new β-cells, and the incomplete
profile of signaling pathways suggest that further investigation is required to harness these
models for potential therapeutic intervention.
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Understanding complete mitogenic pathways from stimulus to downstream signaling to
cell cycle progression is important because not all mitogens translate to productive completion of
the cell cycle. The ability of HNF4α, a nuclear receptor transcription factor, to drive human β-cell
proliferation was investigated based on its requirement for murine β-cell replication in response to
pregnancy and obesity (Gupta et al. 2007). Interestingly, overexpression of the pancreas-specific
isoform HNF4α8 in human β-cells prompted β-cells to enter, but not successfully complete, the
cell cycle (Rieck et al. 2012). Punctate BrdU incorporation along with assessment of other DNA
damage markers suggested an uncoupling of mechanisms regulating the timing of DNA
replication, resulting in cell cycle arrest during S-phase. This study also re-evaluated the ability of
Cdk6 and Cyclin D3 overexpression to stimulate human β-cell proliferation, independently or in
combination with HNF4α8 overexpression. While these cell cycle regulators seemed to push βcells through S-phase, as evident by increased Ki67 staining, the DNA damage response was still
activated, ultimately leading to cell cycle arrest. This study raises several interesting points.
Firstly, the adult human β-cell is capable of initiating cell cycle re-entry. Secondly, surrogate
markers such as BrdU incorporation cannot be used in isolation as readout for β-cell proliferation.
Finally, mechanistic studies in human β-cells are necessary to elucidate why certain stimuli lead
to deregulated cell cycle progression, and in order to prioritize which targets are more likely to
result in completion of the cell cycle.

Adult human β-cells do not readily respond to mitogenic stimuli
Age-related decline in β-cell proliferative capacity
Even though adult β-cell mass exhibits plasticity during metabolic stress, evidence
suggests that the capacity for β-cell regeneration decreases with age (Teta et al. 2005; Kushner
2013). This may even be evident in the pregnancy population, since maternal age greater than 25
is one of several risk factors for gestational diabetes (Cypryk et al. 2008). An age-related decline
in β-cell proliferative capacity has been thoroughly studied in several rodent models. In β-cell
injury models, including partial pancreatectomy and low-dose streptozotocin (STZ), proliferation
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was induced more robustly in young β-cells compared to old β-cells. Similar findings have been
reported in response to mitogenic stimuli, including the glucagon-like peptide 1 (GLP-1) analog
exendin-4 and obesity induced by high fat diet (Rankin and Kushner 2009; Tschen et al. 2009;
Kushner 2013).

This phenomenon was also observed in a non-human primate model, i.e.

middle-aged vervet monkeys, which showed a limited β-cell regenerative response to STZ
(Saisho et al. 2011). Thus, even in the presence of appropriate mitogenic stimuli, β-cells exhibit
decreased ability to respond in an age-dependent fashion.
While studies in human islets are limited, an age-related decline in human β-cell
proliferative capacity has also been reported. In one study, Tian and colleagues transplanted
mouse and human islets from donors of various ages into diabetic mice and administered BrdU
alone or with exendin-4 (Tian et al. 2011). In grafts from both young and old mouse islet donors,
proliferating β-cells were found even without exendin-4 treatment, although the percentage of
proliferating β-cells was higher in young islet grafts. Exendin-4 treatment augmented proliferation
in both young and old β-cells in mouse islet grafts. In the case of human islet donors, exendin-4
augmented β-cell proliferation in grafts from donors younger than 22 years of age. However, very
little β-cell proliferation was detected in treated or untreated mice transplanted with human islets
from donors older than 35 years of age, suggesting decreased proliferative capacity even in the
presence of multiple mitogenic stimuli. This study highlights an important recurring theme, which
is that rodent β-cell findings cannot be directly translated to human β-cell physiology.
What precisely mediates the age-related decline in proliferative capacity is at present
poorly understood. Much attention has been drawn to changes in expression of the cell cycle
machinery with aging, discussed below. Other hypotheses include loss of receptors mediating
mitogenic signaling, age-dependent increase in the replication-refractory period, stochastic aging
due to accumulation of somatic mutations, and cellular damage due to ER stress associated with
secretory cells (Kushner 2013; Papa 2012). An alternative hypothesis is that more broad agerelated changes in the β-cell epigenetic landscape contribute to transcriptional reprogramming,
which may in turn affect expression of genes critical to cell cycle progression.
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p16 contributes to β-cell aging
The human β-cell field is lacking a complete profile of age-associated changes.
Nevertheless, limited human studies in combination with animal studies have led to a rudimentary
model for the age-related decline in β-cell proliferative capacity, and p16, encoded by the
CDKN2A locus, lies in the center of this model. This proposed role of p16 is not surprising, since
CDKN2A expression has been shown to increase with age in most rodent and human tissues,
and has emerged as a biomarker of the aging process. p16 is a master-regulator of cellular
senescence, mediating its effects through the retinoblastoma pathway discussed previously.
Additionally, CDKN2A is consistently a top hit in GWAS studies of age-related disorders including
type 2 diabetes, coronary artery disease, myocardial infarction, and late-onset Alzheimer’s
disease (Martin et al. 2014).
In murine β-cells, p16 is a well-established mediator of age-related decline proliferative
capacity.

It has been demonstrated that decreasing p16 levels through germline gene

inactivation can rescue the proliferative capacity of mouse adult β-cells (Krishnamurthy et al.
2006). Increased expression of Cdkn2a with age appears to be mediated by epigenetic
mechanisms involving polycomb repressive complexes (PRC), PRC1 and PRC2.

PRC2

suppresses transcription by depositing histone 3 lysine 27 trimethylation (H3K27me3), a
repressive histone modification.

PRC1 subsequently recognizes H3K27 trimethylation and

facilitates chromatin compaction by histone 2A (H2A) ubiquitylation, which in turn blocks
recruitment of the histone 3 lysine 4 (H3K4) methyltransferase MLL1 (van Kruijsbergen et al.
2015). Expression of Ezh2, an H3K27 histone methyltransferase associated with PRC2,
decreases with age in murine β-cells, leading to de-repression of the Cdkn2a locus (Chen et al.
2009). PRC1 also contributes to repression of Cdkn2a, and age-related decrease in expression
of Bmi-1, encoding a polycomb group protein that is critical for stability of PRC1, ultimately leads
to transcriptional activation of Cdkn2a by permitting MLL1 recruitment (Dhawan et al. 2009).
Additional studies have revealed that in β-cells Cdkn2a regulation is linked to key cellular
signaling pathways, providing a potential connection between external mitogenic stimuli and cell
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cycle progression. For example, Chen and colleagues reported an age-dependent decline in
platelet-derived growth factor receptor (PDGF) signaling, which attenuated Erk activation and
thereby Ezh2 expression, ultimately leading to increased p16 and decreased β-cell proliferation
(Chen et al. 2011). This age-dependent attenuation of PDGF signaling appeared conserved in
human β-cells as well. Stiles and colleagues also showed that deletion of Pten, a negative
regulator of the PI3K/Akt growth factor signaling pathway, enhanced Ezh2 expression and
thereby H3K27 trimethylation of Cdkn2a, resulting in increased proliferation of adult murine βcells(Zeng et al. 2013).
In humans, age-related accumulation of p16 is also associated with decreased
proliferative capacity of β-cells. Kohler and colleagues correlated β-cell proliferation with protein
levels of p16 and other cell cycle regulators in fetal and adult pancreatic tissue sections (Koehler
et al. 2011). In line with other studies, they reported average proliferation of 3.5% in fetal β-cells
compared to 0.5% in adult β-cells based on co-immunostaining of ki67 and insulin. p16 was
detected in 63.1% of adult β-cells and just 8% of prenatal β-cells.

Limitations in studying human β-cell proliferation
Despite strong interest in β-cell regeneration research, this field has been greatly stunted
due to technical challenges in working with human β-cells. Modeling β-cell replication in vitro has
been a big hurdle, given that β-cell proliferation rates are so low in the adult human. One of the
major obstacles in the field is lack of a human β-cell line. Rodent β-cell lines such as rat INS-1
cells provide a convenient in vitro tool for studying β-cell physiology, but important differences
between rodent and human β-cells, discussed below, have led to a search for a human cell line.
Towards this goal, Ravassard and colleagues developed the EnodC-βH1 cell line, which was
derived by targeted oncogenesis of human fetal pancreas tissue (Ravassard et al. 2011).
However, this targeted oncogenesis procedure involved transformation with the immortalizing
transgenes simian virus 40 large T antigen (SV40LT) and human telomerase reverse
transcriptase (hTERT), making this cell line particularly poorly suited for proliferation studies. To
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address this issue, the same group generated the EndoC-βH2 cell line in which the immortalizing
transgenes can be removed by Cre-mediated gene excision. Removal of the transgenes resulted
in decreased proliferation and improvements in β-cell identity features (Scharfmann et al. 2014).
Despite these advances, EndoC cell lines are notoriously difficult to maintain in culture and have
therefore not yet been put into widespread use.
Without a reliable β-cell line, researchers have turned to primary human islets, which are
obtained from deceased organ donors. Only recently have human islets become more widely
available for research purposes through distribution networks such as the Integrated Islet
Distribution Program (IIDP). The availability of human islets for research is subject to many of the
same limitations as pancreatic islet transplantation, in that donors must meet certain health
criteria, and there is a short window post-mortem during which islets must be isolated. Further,
the cost of conducting research with human islets is quite high in part due to the complex isolation
procedure. Additionally, human islets can only be maintained in culture for a matter of weeks,
meaning that experiments must be short term. Human islet xenotransplantation in mice either
under the kidney capsule or the anterior chamber of the eye is one advance that has permitted
long-term and physiologically relevant experiments. Transplanted human islets start to become
re-vascularized in as little as two days, and can restore euglycemia in diabetic animals (Menger
et al. 2001; Sabek et al. 2005; Sakata et al. 2012).
While rodent models continue to provide invaluable insight into β-cell biology, there are
important differences that suggest caution should be taken when translating these studies into
human physiology. Firstly, islet structure itself differs between the two species in that the mouse
islet is mantled, containing a core of β-cells that make up approximately 80% of the islet
surrounded by a smaller number of other islet endocrine cell types on the periphery (Brissova et
al. 2005; Cabrera et al. 2006). (Figure 1.2A). In contrast, β-cells make up approximately 50% of
the cellular composition in human islets, and all endocrine cell types are scattered throughout the
islet and along the surrounding vasculature (Cabrera et al. 2006). These differences in islet cell
composition and architecture have important implications in functionality.
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For instance, the

mantled structure of the mouse islet lends itself to uniform oscillatory β-cell glucose
responsiveness, which is not observed in the more homogenous human islet (Cabrera et al.
2006). Of particular relevance to the present work are differences in β-cell proliferation capacity
and cell cycle machinery. For example, Cdk6 is present in mouse β-cells while both CDK4 and
CDK6 are present in human β-cells (Salas et al 2014, Fiaschi-Taesch et al 2013). Further, cyclin
D2 expression in mouse β-cells is significantly higher than other D-type cyclins, while in human βcells cyclin D2 protein is not detectable (Salas et al. 2014; Fiaschi-Taesch et al. 2013a). (Figure
1.2B).
In general, mouse β-cells show a much greater capacity for proliferation. For example,
mouse β-cell proliferation in the neonatal period ranges from 10-30%, and this rate is at most 2%
in human neonatal β-cells (Wang et al. 2015c).

Further, many mitogenic stimuli that robustly

activate mouse β-cell proliferation have failed to do so in human β-cells (Wang et al. 2015c).
One striking example of the incongruence between mouse and human β-cell proliferation is the
effect of betatrophin. Melton and colleagues identified betatrophin as a circulating factor released
from the liver that is capable of stimulating rodent β-cell proliferation under insulin resistance
conditions by nearly 20-fold within a few days (Yi et al. 2013). Jiao and colleagues subsequently
confirmed these findings, and proved in a xenotransplantation model that betatrophin has no
effect on proliferation of human β-cells (Jiao et al. 2014). This example highlights the importance
of validating each target in human β-cells.

Epigenetic modification may permit adult human β-cell proliferation
Epigenetics and DNA methylation overview
While cell cycle regulators, such as p16, are reasonable targets for β-cell rejuvenation, it
is possible that changes in levels of these proteins is part of a more widespread aging process,
especially considering the extensive network of pathways implicated in the aging murine β-cell.
Epigenetics, and in particular DNA methylation, is one potential explanation for what might govern
the aging process. Epigenetics refers to heritable changes in gene expression or other traits that
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are not determined by changes in DNA sequence.

There are three broad categories of

epigenetic modifications including DNA methylation, histone modifications, and non-coding RNAs.
DNA methylation is the covalent addition of a methyl group to the C5 position of cytosine
residues, typically in the context of CpG dinucleotides. This mark may be of particular relevance
to the aging process since it is a covalent, and therefore stable, modification directly to DNA, and
is faithfully maintained through subsequent rounds of cell division. DNA methylation was initially
found to function in transcriptional repression, but a more complex role has been increasingly
recognized.
In addition to transcriptional regulation, DNA methylation is critical to maintaining genome
integrity through inactivating transposable elements in repeat regions, for X chromosome
inactivation in females, and to genomic imprinting (Reik et al. 2001).

The landscape of DNA

methylation throughout the genome largely reflects these roles. There are approximately 30
million CpG dinucleotides in the human genome, making up about 1% of total nucleotide content.
A fraction of these CpGs, 1-2%, are clustered in highly dense areas known as CpG islands
(CGIs), while the majority of CpGs are dispersed sparsely throughout the genome. A CGI is
defined as a region greater than 500 bps with more than 50% CpG content (Zampieri et al.
2015). More than half of all CGIs are associated with coding gene promoters, directly regulating
gene expression by determining whether or not transcriptional machinery can bind.

Further,

about 60-70% of all genes contain CGIs within the promoter region (Jones et al. 2015).

The

majority of the genome is highly methylated, which promotes genomic stability by limiting the
activity of transposable elements, while certain regulatory elements, including CGIs and
enhancers, are usually lowly methylated (Stadler et al. 2011; Sheaffer et al. 2014).
Although DNA methylation is considered to be a generally stable epigenetic modification,
dynamic DNA methylation remodeling is crucial to embryonic development in mammals. Postfertilization, the preimplantation embryo undergoes genome-wide DNA de-methylation in order to
maintain cellular totipotency. After implantation, DNA methylation patters are re-established to
direct cellular differentiation. A similar process of de-methylation followed by re-methylation is
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observed in the development of primordial germ cells (Zampieri et al. 2015).

These dramatic

remodeling processes are somewhat in contrast to what is observed with respect to DNA
methylation and aging, a phenomenon known as epigenetic drift.

DNA methylation and β-cell aging
The term “epigenetic drift” refers to non-directional changes to the epigenome that occur
with age. Thus, there is in general a greater concordance of CpG methylation patterns between
younger individuals than between older individuals. Perhaps the most convincing example of
epigenetic drift is in the case of monozygotic twins, in which it has been found that younger twin
pairs are more epigenetically similar than older twin pairs as measured by methylated cytosine
genomic content and acetylation levels of histones H3 and H4 (Fraga et al. 2005). Lifestyle and
the amount of lifetime spent together further contributed to epigenetic differences between
monozygotic twins. Such differences occurred throughout the genome in both repeat and singlecopy genes, and were correlated with gene expression. These studies suggest that a general
divergence of the epigenome with age is due to both environmental influences and stochastic
errors that occur with time. Simultaneously, certain directional changes have been observed with
age, described by some as the “epigenetic clock” (Jones et al. 2015). Individual CpG sites can
even be used to predict chronological age.

Hannum and colleagues developed a predictive

model for apparent methylomic aging rate (AMAR) based on a set of 71 methylation markers, and
were able to predict age with an accuracy of 91% within 4.9 years

(Hannum et al. 2013).

Additionally, a study by Wagner and colleagues demonstrated that in blood samples, age could
be predicted within five years from measuring DNA methylation at just three CpG sites (Weidner
et al. 2014).
Directional changes can be considered in two groups, regions that lose methylation with
age and regions that gain methylation with age. These changes can be summarized as genomewide hypomethylation with specific sites susceptible to hypermethylation, particularly within CGI
promoters (Zampieri et al. 2015). A study conducted by Heyn and colleagues compared DNA
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methylomes of CD4+ T cells from a newborn and centenarian by whole genome bisulfite
sequencing (WGBS) (Heyn et al. 2012). The centenarian genome was hypomethylated and less
homogenously methylated than that of the newborn. They found 17,930 differentially methylated
regions (DMRs) covering 2.2% of all CpGs, and only 13% of these were hypermethylation events.
These DMRs spanned all genomic compartments, but the majority were within intronic and
intergenic regions, and only 10% were within promoter regions. Further, 36% of DMRs occurred
within lamin-associated domains (LADs).

Interestingly, several laminopathies such as

Hutchinson-Guilford Progeria Syndrome (HGPS) are characterized by premature aging,
suggesting a potential connection between defective nuclear lamina, aging, and the epigenomic
landscape (Heyn et al. 2013). Hypermethylation events are rare but significant in the aging DNA
methylome.

Some studies have found age-associated increases in DNA methylation to be

preferentially located in CGIs, common in promoters, and these changes are frequently
associated with inactivation of the corresponding gene.

Genes that undergo promoter

hypermethylation with age are often associated with age-related disorders such as cancer and
neurodegeneration (Zampieri et al. 2015).
The role of DNA methylation has been recently investigated specifically in the aging
murine β-cell, with the hypothesis that changes in DNA methylation may contribute to the agerelated decline in proliferative capacity.

An integrative analysis was conducted of DNA

methylation, histone modifications, gene expression and β-cell function in prepubescent and postfertile aged murine β-cells (Avrahami et al. 2015).

In line with other aging DNA methylome

studies, this study demonstrated genome-wide epigenetic drift coupled with targeted changes in
distal regulatory elements. Epigenetic drift resulted in a leveling of the DNA methylome, while
targeted changes were associated with cell cycle and β-cell function genes. Indeed, this study
identified age-related changes in Cdkn2a DNA methylation at putative distal regulatory elements
that correlate with increased Cdkn2a expression in aged mouse β-cells. Interestingly, these agerelated changes were associated with activation of metabolic regulators and improved β-cell
function, challenging the current paradigm of β-cell failure as purely an aging phenomenon. This
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study has laid much of the groundwork for investigating epigenetic rejuvenation of aging β-cells,
and one goal of the present work is to create a similar epigenetic aging profile for human β-cells.

Strategies for modifying DNA methylation
A portion of this section was adapted from published work: Bernstein DL, Le Lay JE,
Ruano EG, Kaestner KH.

TALE-mediated epigenetic suppression of CDKN2A increases

replication in human fibroblasts. J Clin Invest. 2015 May;125(5):1998-2006.
A critical consideration for pursuing epigenetic rejuvenation of adult human β-cells as a
therapeutic strategy for diabetes is how to perturb DNA methylation in a targeted fashion.
Epigenetic therapeutics to date are limited to small molecule inhibitors that target ubiquitously
expressed epigenetic regulators, including DNA methyltransferases. Thus, the entire genome,
and the entire organism when administered systemically, is susceptible to the effects of such
drugs. The role for DNA methylation in establishing and maintaining functional β-cells is being
increasingly recognized, both in a normal and diseased state, highlighting the importance of
targeted strategies. For example, it has recently been shown in mice that DNA methylation
facilitates the functional maturation of postnatal β-cells

(Dhawan et al. 2015).

Further, as

discussed, DNA methylation might play a role in enhancing β-cell function with age (Avrahami et
al. 2015).

On the other hand, a number of CpG susceptibility loci have connected DNA

methylation and type 2 diabetes (Dayeh et al. 2014). Similarly, another study concluded that the
promoter of the DLK1-MEG3 microRNA cluster is hypermethylated in type 2 diabetics, leading to
decreased expression of this microRNA cluster, which regulates target genes that contribute to βcell apoptosis (Kameswaran et al. 2014). Thus, one can anticipate the potential concerns with
modifying DNA methylation at the genome-wide level in the β-cell, necessitating the modification
of DNA methylation in a cell-type and locus-specific manner.
The main strategy for targeted epigenetic editing is fusion of catalytic domains of
epigenetic modifiers to custom DNA binding proteins targeting genes of interest.

The clear

advantage of targeted epigenetic editing over targeted transcriptional activation or repression is
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the potential to have a more stable impact on gene expression. Further, epigenetic modifications
can be targeted to proximal or distal regulatory elements rather than simply promoters, which
may be especially important in the context of aging. Current approaches include zinc fingers,
TALEs, and clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR
associated protein 9 (Cas9). Zinc fingers represent one of the earliest examples of engineered
DNA binding proteins, and have been coupled to a wide range of effector domains, including DNA
methyltransferases, as discussed earlier. Zinc finger DNA binding modules interact with a series
of three base pairs, somewhat limiting potential target sequences. Therefore, TALEs have largely
replaced zinc fingers in these efforts since they are extremely modular, inexpensive, and quick to
assemble.
TALEs are DNA binding proteins endogenous to bacterial plant pathogens including the
genus Xanthomonas.

This class of proteins binds to specific regulatory regions in the host

genome to modulate gene expression and promote bacteria survival. The central DNA binding
domain of TALE proteins consists of a series of approximately 34-amino acid repeats, or
monomers, which are polymorphic only at positions 12 and 13. These polymorphic residues,
termed the repeat-variable-di-residue (RVD), determine DNA binding specificity, as each amino
acid pair preferentially binds to one of the four nucleotides (Cermak et al. 2011). Consequently,
by assembling monomers in a particular order, TALEs can be engineered to bind specific DNA
sequences.
Customized TALEs have been used to modulate transcription through conjugation to
activator domains, such as VP64, and repressor domains, such as the mSin interaction domain
(SID) (Morbitzer et al. 2010; Cong et al. 2012). More recently, TALEs have been employed to
introduce targeted epigenetic changes such as histone demethylation, DNA methylation and DNA
de-methylation, which have resulted in altered gene expression (Mendenhall et al. 2013; Maeder
et al. 2013; Bernstein et al. 2015b). To our knowledge, we are the only group to date that has
demonstrated a biological impact of targeted epigenetic editing, and we did so by decreasing
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CDKN2A expression in primary human fibroblasts by targeted DNA methylation in order to
increase proliferation (Bernstein et al. 2015b).
Shortly after the introduction of TALEs and TALE nucleases (TALENs), the CRISPRCas9 system emerged as an exciting new tool for genomic engineering. With this system, the
Cas9 nuclease is guided to a target genomic DNA sequence by complementary base pair binding
of a guide RNA (gRNA). Progress has been made in optimizing this tool for genomic engineering
in the past several years, and the field is now expanding into transcriptional regulation with the
use of a catalytically deactivated, or dCas9, nuclease fused to transcriptional regulators or
epigenetic modifiers. dCas9 has been employed for targeted epigenetic modification by fusing
dCas9 to the p300 acetyltransferase or Kruppel-associated box (KRAB) repressor in order to
activate and repress gene expression, respectively (Hilton et al. 2015; Thakore et al. 2015). The
key potential advantage of CRISPR-Cas9 over TALEs is the flexibility in using guide RNAs rather
than proteins for DNA targeting. Further, it might be possible to simultaneously target multiple
genes by using multiple gRNAs with a single Cas9 fusion protein. However, in some instances
multiple gRNAs are required to affect expression of a single gene, warranting further investigation
into what facilitates sufficient targeting (Hilton et al. 2015). Despite differences in underlying
mechanisms, any of these systems are subject to potential off-target effects, and improving
specificity is an ongoing challenge in the field. The preferred method is likely to be determined in
a context-dependent manner.

Summary
β-cell replacement therapy holds the potential to cure diabetes, although limited sources
of β-cells have hindered its widespread clinical application. A key challenge in the field is that
proliferative capacity of β-cells decreases with age, which may be caused by changes in
epigenetic marks such as DNA methylation. We hypothesize that age-related changes in DNA
methylation contribute to transcriptional changes that facilitate reduced proliferative capacity in
adult human β-cells. There is an overwhelming need for a comprehensive landscape of the aging
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human β-cell, and tools to modify gene expression in a targeted fashion. The focus of this thesis
was to develop resources for targeted DNA methylation to alter gene expression and thereby
stimulate cell cycle progression, and to determine the methylome of the human β-cell during the
aging process. Chapter 2 describes the transcriptome and DNA methylome of β-cells throughout
the human lifespan. Chapter 3 presents a novel technique of fusing custom DNA binding proteins,
TALEs, to DNA methyltransferase catalytic domains to specifically methylate target genes and
thereby decrease gene expression (Bernstein et al. 2015b).

p16 was selected as a target for

validating this approach in primary human fibroblasts given the demonstrated role of p16 in
2

decreased proliferative capacity of murine β-cells. Finally, in Chapter 4, I present BisPCR , a
high-throughput and efficient method for targeted bisulfite next-generation sequencing (Bernstein
et al. 2015a). These resources may be useful in epigenetic rejuvenation of human adult β-cells,
and in the more broad DNA methylation research community.
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Figure 1.1.

Human β-cell proliferation during the human lifespan.

Graph illustrates

approximate insulin and Ki67 co-positive cells as a percentage of total insulin positive cells in
human cadaver sections across the human lifespan quantified by immunohistochemistry. Note
peak proliferation occurs in the early neonatal period and represents only about 2% of β-cells.
Proliferation drops off rapidly in early childhood and is not readily detectable in adulthood. Figure
published in: Wang, P. et al. Diabetes mellitus-advances and challenges in human beta-cell
proliferation. Nature Reviews Endocrinology, 2015; 11(4): 201-212.
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Figure 1.2. Mouse islets are not directly comparable to human islets. (A) Comparison of
mouse islet structure to human islet structure.

The mouse islet consists of a β-cell core

surrounded by a mantle of other endocrine cell types, and β-cells constitute approximately 80% of
all cells. In the human islet, endocrine subtypes are dispersed throughout the islet, and β-cells
make up about 50% of all cells. (B) Key regulators in the β-cell G1/S cell cycle checkpoint. Two
key differences between mouse and human β-cells, identified by red text, are the presence of
CDK6 and the absence of cyclin D2 in human β-cells. Positive cell cycle regulators are indicated
in blue and negative cell cycle regulators are indicated in orange. Gray indicates epigenetic
regulators of CDKN2A (p16).
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Figure 1.3. TALE-DNMT fusion proteins for targeted DNA methylation. The repeat domain,
or DNA binding domain, of transcription activator-like effectors (TALEs) consists of a series of
monomers, each 34 amino acids long. These monomers are identical in amino acid sequence
th

th

with the exception of the amino acids at the 12 and 13 position, termed the repeat variable diresidue (RVD), which determines which nucleotide the monomer interacts with. The series of
monomers thereby determine TALE DNA binding specificity. Conjugating DNA methyltransferase
(DNMT) catalytic domains DNMT3a and DNMT3L permits targeted DNA methylation to the
genomic region specified by the DNA binding domain. The amino acid RVD that preferentially
interacts with each nucleotide is listed in the legend on the right of the diagram. N-Term, NTerminus; C-Term, C-Terminus.
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CHAPTER 2 – Profiling the human β-cell DNA methylome and transcriptome from
birth to mature age.
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Abstract
Pancreatic β-cell replacement therapy holds the potential to cure diabetes, although its
widespread implementation has been limited due to a shortage of organ donors. One strategy to
increase the supply of human β-cells is to induce proliferation of pre-existing cells. This strategy
is hindered by the fact that proliferative capacity of human β-cells decreases with age.

We

hypothesized that this age-dependent decline in proliferative capacity is accompanied by
transcriptional changes that are dependent on changes in DNA methylation. Thus, we sought to
profile the transcriptome and DNA methylome of β-cells across the human lifespan. We isolated
human β-cells from 23 deceased organ donors ranging in age from three-months old to 64-years
old and conducted RNA-Seq. For a subset of samples we also performed whole-genome bisulfite
sequencing (WGBS) to assess DNA methylation at single-base resolution, and integrated DNA
methylome data with published datasets for human islet chromatin states and transcription factor
binding. We found that expression of key cell cycle inhibitors increases, while certain β-cellspecific transcription factors are de-activated with age.

Further, we found that the DNA

methylome is dynamic during human life, and that these changes occur preferentially at isletspecific active enhancers that lose methylation with age. Future efforts will be directed towards
integrating gene expression and DNA methylation findings in a comprehensive fashion.
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Introduction
Pancreatic β-cells lose the ability to proliferate with age, and restoring proliferative
capacity in adult β-cells is an attractive therapeutic opportunity for treating diabetes. This agerelated decline in proliferative capacity has been extensively studied in rodent model systems,
and it has been clearly demonstrated that older β-cells do not respond as well as younger β-cells
in β-cell injury models or in response to mitogenic stimuli (Rankin and Kushner 2009; Tschen et
al. 2009; Kushner 2013). Due to challenges of working with primary human islets, human β-cell
proliferation studies to date have largely been limited to candidate target approaches based on
these rodent studies (Takane et al. 2012; Fiaschi-Taesch et al. 2010; Cozar-Castellano et al.
2004; Rieck et al. 2012).

However, important differences between rodent and human β-cell

proliferation prevent direct translation, and thus the β-cell regeneration field is in need of a
comprehensive profile of the aging human β-cell (Kulkarni et al. 2012).
Since aging phenotypes are not likely the consequence of changes in DNA sequence, it
is probable that epigenetic modifications, and in particular DNA methylation, contribute to the
aging process (Heyn et al. 2012; Zampieri et al. 2015; Jones et al. 2015; Avrahami et al. 2015).
DNA methylation is defined by the addition of a methyl group most commonly to the 5C position
of cytosine residues in the context of CpG dinucleotides.

This mark is faithfully maintained

through subsequent rounds of DNA replication by remethylation of the newly synthesized DNA
strand by DNA methyltransferase 1 (DNMT1), and thus has long been considered to be stable.
However, recent studies in humans have demonstrated that DNA methylation at certain genomic
regions, such as promoters and distal regulatory elements, is in fact dynamic during aging (Heyn
et al. 2012; McClay et al. 2014; Xiao et al. 2015).
Transcriptional reprogramming mediated by changes in DNA methylation with age is one
possible explanation for reduced proliferation in adult human β-cells. Indeed, recent work by
Avrahami and colleagues has demonstrated a compelling role for DNA methylation in mediating
the decline in proliferative capacity of rodent β-cells (Avrahami et al. 2015). This study included
an integrative analysis of genome-wide DNA methylation, gene expression, histone modifications,
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and β-cell-specific transcription factor binding, comparing pre-pubescent and post-fertile age
mice. Age-related changes in DNA methylation occurred preferentially at cell cycle regulators
and also at important β-cell function genes, which correlated with an improvement in β-cell
function.
We sought to build a similar profile of the aging human β-cell to investigate changes in
gene expression and the potential role of DNA methylation in this process. We also sought to
incorporate published datasets for genome-wide chromatin states and transcription factor binding
in whole islets in order to better characterize differentially methylated regions (DMRs). Towards
this goal, we conducted RNA-Seq transcriptome profiling in β-cells across the human lifespan,
ranging in age from three-months to 64-years old. For a subset of these samples, we also
performed whole genome shotgun bisulfite sequencing (WGBS) to profile the aging human β-cell
methylome at single base resolution.

In the present work, we have established the

aforementioned datasets and have begun to characterize the dynamics of DNA methylation in the
aging human β-cell. Ongoing efforts include integration of gene expression data and further
analyses to determine precisely how DNA methylation contributes to the reduced proliferative
capacity in human β-cells with age.

Results
In order to assess the contribution of DNA methylation to the age-related decline in
human β-cell proliferation, we profiled gene expression and genome-wide DNA methylation at
single base resolution for β-cells across the human lifespan, and incorporated published datasets
of human whole islet chromatin states and transcription factor occupancy (Figure 2.1A). Twentythree human islet samples from deceased organ donors were dispersed and FACS-sorted to
isolate β-cells using cell surface antibodies developed by Dorrell and colleagues (Dorrell et al.
2008).

Genomic DNA and mRNA were extracted, and whole genome shotgun bisulfite

sequencing (WGBS) was performed on a subset of 8 samples, while RNA-Seq was performed for
all 23 samples (Table 2.1). One sample, ICRH51, a four-year old donor, was determined to be a
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putative outlier and was excluded from further analysis for both gene expression and DNA
methylation. WGBS samples included three young donors (6 months, 2 years and 8 years of
age), and three old donors (47, 59, and 60 years of age). We also included an 18-year old donor
sample to assess a potential intermediate phenotype in our analysis, similar to the approach
taken for the analysis of the CD4+ T cell methylome (Heyn et al. 2012).

Characterization of old and young human β-cell DNA methylomes
We first assessed global DNA methylation patterns in young and old human β-cells. As
anticipated, the majority of the genome in both young and old human β-cells is highly methylated,
while promoters are largely unmethylated (Figure 2.1B). In our WGBS analysis we applied the
Hidden Markov Model developed by Stadler and colleagues to segment the methylome into three
categories including fully methylated regions (FMRs) (> 50% methylation), lowly methylated
regions (LMRs) (13.9 to 50% methylation), and unmethylated regions (< 13.9% methylation)
(Stadler et al 2011). We further narrowed our DNA methylome analysis to LMRs and UMRs to
isolate potential regulatory elements such as promoters and enhancers. We then categorized
LMRs and UMRs for young and old β-cells by genomic elements such as proximal promoters or
repeat elements (Figures 2.1C and 2.1D). We found a very similar number and distribution of
LMRs and UMRs in young and old β-cells, confirming the general uniformity in DNA methylation
between the two groups.

Differentially methylated regions between young and old human β-cells
After characterizing genome-wide DNA methylation in young and old human β-cells, we
next identified differentially methylated regions (DMRs) by comparing the average methylation of
the union of LMRs and UMRs between young and old samples. In other words, we excluded
from our analysis all genomic regions that are fully methylated during ontogeny, as these
represent mostly repetitive regions and other non-dynamic genomic sequences. Using a false
discovery rate of 10%, a minimum of four CpGs per regions, and a minimum difference in
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average methylation between young and old samples of 5%, we identified 1,082 DMRs, 588 of
which lost methylation with age and 494 of which gained methylation with age (Figure 2.2A). A
greater average magnitude of change was observed in regions that lost methylation with age
compared to those that gained methylation with age (Figure 2.2A). We further grouped DMRs
that gained or lost methylation with age by genomic region and found that the majority of DMRs
occur in intergenic regions, regardless of the direction of change (Figure 2.2B).

DMRs at

intergenic regions may be indicative of distal regulatory elements, such as enhancers or
silencers, as found in several prior studies (Stadler et al. 2011; Sheaffer et al. 2014; Avrahami et
al. 2015).

The remainder of regions that gain methylation with age are relatively evenly

distributed among repeats, exons, and introns, while the remainder of regions that lose
methylation with age are mainly located within introns. The magnitude and direction of changes
in methylation within each genomic compartment is illustrated in Figure 2.2C, again emphasizing
that the magnitude of change is greater in regions that lose methylation with age. We also
conducted a clustering analysis of DMRs across all seven WGBS samples and found that while
the extreme old and young ages were quite similar to each other, the 18-year old donor sample
showed an intermediate pattern, suggesting changes in DNA methylation occur gradually over
the human lifespan (Figure 2.2D).

LMRs and UMRs correlate with human islet regulatory regions
Next, we focused our analysis on LMRs and UMRs because of their high likelihood of
being regulatory regions.

We wanted to further interrogate this possibility by incorporating

published datasets of chromatin states in human islets.

Pasquali and colleagues have

assembled a profile of human islet regulatory regions by integrating open chromatin maps with
key histone marks, CTCF binding sites, and islet-specific transcription factor binding sites
(Pasquali et al. 2014). Open chromatin sites were first determined by FAIRE-Seq in combination
with ChIP-Seq for histone 2A.Z (H2A.Z). Histone marks assessed include histone 3 lysine 4
monomethylation (H3K4me1), histone 3 lysine 4 trimethylation (H3K4me3), and acetylation of
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histone H3 at lysine 27 (H3K27ac). Based on these datasets, Pasquali and colleagues defined
five classes of regulatory regions, including promoters (C1), inactive enhancers (C2), active
enhancers (C3), CCCTC-Binding Factor (CTCF) bound sites (C4), and other accessible
chromatin sites (C5). One key finding of this study was that active enhancers (C3) determine
expression of islet-specific genes, and are preferentially bound by islet-specific transcription
factors.

We investigated whether DNA methylation levels correlated with these regulatory

regions, and whether DMRs specifically were enriched for any given category, such as active
enhancers (C3).
We first performed hierarchical clustering analysis of our LMR/UMR regions and each of
the promoter (C1), inactive enhancer (C2), and active enhancer (C3) accessible chromatin sites,
requiring that the center of the chromatin element defined by Pasquali and colleagues be
contained within a UMR or LMR (Figure 2.3A, 2.3B and 2.3C).

We found that 11,654

UMRs/LMRs overlapped with C1 sites, and that DNA methylation is largely unchanged across
these sites with age (Figure 2.3A). At inactive enhancers, 12,482 LMRs/UMRs overlapped with
C2 sites, and there was an overall trend of decreased methylation with age. This loss of DNA
methylation with age was even more pronounced in active enhancers, in which 18,076
LMRs/UMRs overlapped with C3 sites. The magnitude of demethylation, here represented by a
change in color, was larger for active than for inactive enhancers.
We next determined how the C1-C5 regions overlapped with our LMR/UMR set. We
found that there was a highly significant preferential overlap of the C1-C4 accessible chromatin
sites with LMRs/UMRs compared to the random genomic background defined by a set of 1,000
-10

randomly selected genes (p-value < 10 ) (Figure 2.3D). Nearly all promoter (C1) regions were
identified as an LMR/UMR, confirming that low levels of DNA methylation correlate with promoterassociated histone marks. Further, this finding also suggests that chromatin states at promoters
are similar between sorted β-cells (our data) and whole islets, which is not surprising given the
highly similar chromatin states of the two most abundant endocrine cell types, the α- and β-cell
(Pasquali et al. 2014; Bramswig et al. 2013). Similarly, roughly 90% of CTCF-bound (C4) regions
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overlapped with LMR/UMRs, which is also expected since DNA methylation inhibits CTCFbinding (Phillips and Corces 2009; Wang et al. 2012). Approximately 50% of inactive enhancer
(C2) sites and 75% of active enhancer (C3) sites were identified as LMRs/UMRs. It makes sense
that only half of inactive enhancers (C2) were identified as LMRs or UMRs, since they may be
more likely to be highly methylated (FMRs). Following the same logic, it is also reasonable that a
greater portion of active enhancer (C3) sites overlap with LMRs and UMRs. Further, we and
others, have shown that distal regulatory elements, such as enhancers, are critical in cell-type
specific gene expression

(Stadler et al. 2011; Sheaffer et al. 2014; Avrahami et al. 2015).

Differences in cell types may account for further differences between DNA methylation and
chromatin state.

Islet-specific active enhancers lose methylation with age
Having identified over 1,000 regions that show dynamic DNA methylation with age, we
wanted to investigate chromatin state at DMRs to better understand if certain classes of
regulatory regions are enriched. We overlapped DMRs with C1-C5 open chromatin sites and
found that slightly less than half of the DMRs were also classified as one of these five regions, the
most common being enhancers (C2 and C3) (Figures 2.3E and 2.3F). Since at this point we
have narrowed down our analysis to age-related changes in DNA methylation in the β-cell, it is
possible that the remaining DMRs are β-cell-specific and thus may not have been identified in the
study of whole islets. This set of regions will need to be analyzed independently. The most
prominent groups amongst the C1-C5 overlapping regions were active enhancers that lose
methylation with age (207 regions) and inactive enhancers that gain methylation with age (73
regions) (Figure 2.3G). Demethylation of putative distal regulatory elements has been previously
reported in the aging murine β-cell, and it will be interesting to investigate this group of regions in
further detail (Avrahami et al. 2015).
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Identifying age-related patterns in gene expression
Because our data represent a continuum of age, rather than two distinct classes of
“young” and “old” β-cells, as was done for the murine aging study, we attempted a time course
analysis of gene expression versus age (Figure 2.4). Our goal was to use this time course
analysis to identify critical regulators of proliferative capacity, and then to overlap this gene set
with DMRs to elucidate a role for DNA methylation in regulating the aging process. We decided
to conduct regression analyses with both linear and log-linear models. Unfortunately, our RNASeq datasets were collected over a period of more than five years, and changes in RNA-Seq
library preparation chemistry made by Illumina led to significant batch effects. Thus, the datasets
were subject to multiple layers of normalization.
Nevertheless, the most significant gene expression of which increased with age in a
linear fashion was CDKN2A, which encodes the cell cycle inhibitor p16, and is strongly implicated
in the age-related decline in proliferative capacity in murine β-cells (Krishnamurthy et al. 2006).
We also found mRNA levels of another cell cycle inhibitor, CDKN2C (p18), to increase
significantly with age, but in a log-linear fashion. Further, amongst the genes that are downregulated with age are three β-cell-specific transcription factors, HNF4α, ISL1 and PDX1.
Genetic variants of each of these genes have been associated with diabetes, and these
transcription factors have been associated with proliferation and may interact with cell cycle
machinery (Bernardo et al. 2008; Yamagata 2014; Guo et al. 2011).

This linear regression

analysis is useful in identifying a subset of genes that change in an age-related fashion, but
importantly, it omits other possibilities such as step-wise changes. Of these genes of interest,
only CDKN2A is associated with DMRs, suggesting that the expression data should also be
analyzed independently from DNA methylation.

Discussion
Here, we report 23 RNA-Seq and 7 WGBS datasets for β-cells throughout the human
lifespan. We began our analysis with a comparison of DNA methylation in young and old human
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β-cells.

As identical cell types, until five years ago the dogma predicted that the DNA

methylomes of young and old human β-cells are identical, because DNA methyltransferase 1
faithfully remethylates the hemi-methylated DNA during and after S-phase.

Remarkably, we

observed over 1,000 significant changes with age, which we argue are there by design, as they
are not distributed randomly over the whole genome, but rather localized to specific regulatory
elements.
When the DNA methylome had been analyzed during murine aging β-cell, it was found
that differentially methylated regions that lose methylation with aging were highly enriched for
binding of β-cell transcription factors such as Pdx1, leading to the hypothesis that transcription
factor binding in young β-cells marks specific regions for eventual demethylation (Avrahami et al.
2015).

Therefore, we will further characterize these regions for transcription factor binding by

motif analysis and by integrating whole islet transcription factor binding maps in the future. It will
also be interesting to investigate those DMRs (approximately 50%) that did not overlap with
previously reported islet regulatory regions. One obvious explanation is that these DMRs are βcell-specific and therefore were not identified in the whole islet approach. A comparison of DNA
methylation in α-cells at a subset of these regions might confirm whether or not they are β-cellspecific. These DMRs could also fall in genomic compartments not represented in the C1-C5
regions, such as repeats or exons. Nevertheless, active enhancers are a particularly exciting
starting point for future analyses.
The critical outstanding component of our analysis is the integration of our gene
expression with our DNA methylation data. We plan to approach this in multiple ways. First, we
will continue to pursue the time course analysis to identify genes that behave similarly in the
aging process. Due to the technical challenges we have encountered with this approach, we will
also conduct a traditional two-state differential expression analysis of the extreme samples. A
third strategy is to categorize samples into age groups including pre-pubescent, pubescent,
young adult and adult. This third strategy may be preferred since it incorporates the principles of
a time course analysis while permitting replicates and therefore greater statistical power.
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A key challenge in assessing genome-wide DNA methylation is associating differentially
methylated regions with genes. The DNA methylome field has adopted a standard of assigning
genes based on the relative position of DMRs to the nearest transcription start site (TSS). While
this strategy has led to useful insights about transcriptional regulation by DNA methylation, it is
also likely to result in many mis-assigned DMR/gene relationships, as enhancers in particular are
subject to chromatin looping interactions and can regulate promoters more than a million bases
distal. Thus, the closest gene may not be the only possible gene affected by a DMR. For
example, an enhancer located in an intron at the microRNA cluster MEG3 locus in human islets
interacts not only with the MEG3 promoter, but also with the promoter of the protein-coding gene
DLK1, and a second islet enhancer cluster that are each roughly 100 kb from the enhancer itself
(personal communication with Vasumathi Kameswaran).
We have made significant progress in building datasets that will lay the foundation for the
aging human β-cell epigenome and transcriptome atlas.

We have profiled gene expression

across the human lifespan, which can be used to assess changes in receptors, signaling
pathways, and the cell cycle machinery that may lead to declined proliferative capacity in adult
human β-cells. We have also determined the DNA methylome of young and old human β-cells to
begin to understand the potential role of DNA methylation in the aging process. While we have
started to characterize age-related changes in DNA methylation, much work remains to be done
to understand transcriptional reprogramming in aging human β-cells and the precise mechanism
by which DNA methylation may contribute.

Methods
Human β-cell isolation
Islets from deceased organ donors were obtained from either the Diabetes Research
Center of the University of Pennsylvania or the Integrated Islet Distribution Program (IIDP).
Human β-cells were isolated from whole islets using fluorescence-activated cell sorting (FACS)
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with cell surface antibodies developed by Dorrell and colleagues (Dorrell et al. 2008).

Genomic

DNA and mRNA were extracted with the AllPrep DNA/RNA kit (Qiagen GmbH).

RNA-Seq
RNA-Seq libraries were prepared by the Next Generation Sequencing Core (NGSC) at
the University of Pennsylvania (Philadelphia, PA) using the Ribo-Zero™ H/M/R Kit (6rxns) (Cat.
No. MRZH116) with TruSeq™ RNA Sample Prep Kit, (Cat. No. RS-122-2001), and then TruSeq®
Stranded Total RNA LT, cat #RS-122-2301 when the unstranded kit was discontinued in 2014.
Sequencing and alignment were also performed by the Next Generation Sequencing Core
(NGSC) at the University of Pennsylvania (Philadelphia, PA) as previously described except that
sequences were aligned to the hg19 genome (Bramswig et al. 2013).
Linear and log-linear regression analyses were performed by the lab of Dr. Kyoung-Jae
Won at the University of Pennsylvania (Philadelphia, PA). Genes were initially selected for a
minimum FPKM (fragments per kb per million) greater than 0.5 in at least six samples and a
minimum fold-change greater than two between minimum and maximum samples. Additional
gene filtering was applied to remove exocrine-specific genes, which represent contamination
(Bramswig et al 2013), and Chromosome Y genes to prevent gender bias. RNA-Seq libraries
were prepared with two slightly different kits, and thus batch effect correction was applied to each
batch independently, which was possible because each batch contained an even distribution of
ages.

Loess normalization was then applied, and finally the linear regression analysis was

conducted using the lm() function in R.

Whole-genome shotgun bisulfite sequencing (WGBS)
WGBS libraries were prepared using the Ovation® Ultralow Methyl-Seq Library Systems
(NuGEN Technologies Inc.) per manufacturer’s instructions.

150ng of genomic DNA was

sonicated using the M220 Focused-ultrasonicator™ (Covaris®) to shear DNA into approximately
400 base pair fragments.

The Ovation® system was then used for end repair, ligation of
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adaptors, and final repair steps.

Next, samples were subjected to bisulfite conversion and

purification with the EpiTect Fast DNA Bisulfite Kit (Qiagen GmbH). Bisulfite conversion was
conducted under the cycling conditions recommended in the Ovation® Ultralow Methyl-Seq
Library procedure. Converted libraries were amplified, purified, and pooled for next generation
sequencing (NGS). Sequencing and DNA methylation analyses were performed by the Next
Generation Sequencing Core at the University of Pennsylvania (Philadelphia, PA). Sequences
were aligned to the human (hg19) genome using BSeeker (Chen et al 2010). Average coverage
was greater than 15X per CpG for each sample. Segmentation of the methylome was conducted
as previously described (Avrahami et al 2015).

To identify differentially methylated regions

(DMRs), average DNA methylation was calculated among the three young or the three old
samples for each CpG in a segment, and then average methylation was calculated across the
segment. Only CpGs with more than 10 reads for each sample were considered, and segments
required a minimum of four CpGs. Average methylation for each segment was compared by a
two-tailed unpaired t-test (p-value < 0.05), and regions with a change greater than 5% were
determined to be differentially methylated.

Analysis of these datasets was performed in

collaboration with Dr. Kyoung-Jae Won’s lab and the Next Generation Sequencing Core (NGSC)
at the University of Pennsylvania (Philadelphia, PA).
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Table 2.1. Human islet donor information.

ID#

Age#(yrs)# Sex# BMI#

RNA2Seq## RNA2Seq##
(old#kit)# (new#kit)#

ACFU423(

3(mo(

F(

NA(

ICRH53(

6(mo(

F(

14.2(

ICRH80(

19(mo(

F(

18(

ICRH76(

2(

M( 13.6(

ICRH51(

4(

F(

16.1(

!

!

ICRH59(

8(

M(

NA(

!

!

CITH86(

10(

F(

NA(

!

ICRH46(

14(

M( 27.1(

!

ICRH75(

17(

F(

22.6(

ICRH52(

18(

M(

NA(

!

AAHP353(

19(

M( 26.9(

!

HP:15031:01(

23(

F(

ICRH41(

28(

M( 24.2(

!

ICRH57(

40(

M(

NA(

!

!
!

!

!

!
!

!

!
!

32.5(

!

ICRH25(

47(

M( 28.3(

!

ABEL98(

47(

F(

26.5(

!

CITH53(

49(

F(

NA(

!

ICRH39(

50(

M( 29.1(

!

CITH68(

52(

M(

NA(

!

AAA1323(

53(

F(

28.4(

!

ACFC227(

59(

F(

23.1(

ABEF248(

60(

F(

34.5(

!

AAAL88(

64(

M( 25.4(

!

!
!
!
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Figure 2.1. Determination of the DNA methylome in young and old human β-cells. (A)
Experimental schema for assessing the role of DNA methylation in the human β-cell during the
aging process. RNA-Seq and whole genome shotgun bisulfite sequencing (WGBS) were
performed on young and old sorted human β-cells to identify differentially methylated regions
(DMRs) that might contribute to changes in transcriptional regulation with age.

DMRs were

further characterized by integrating published datasets on chromatin state and islet-specific
transcription factor binding sites obtained from whole islets, distinguished by grey outlines
(Pasquali et al 2014). (B) Genome-wide distribution of CpG methylation in young and old human
β-cells.

In young and old human β-cells, the entire genome is largely methylated, with the
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exception of proximal promoters and 5’ untranslated regions (UTRs), as expected.

mCpG,

methylated CpGs. Genomic regions were defined as: distal, -1 kb to -5 kb from TSS; proximal, 0
to -1 kb from the TSS; caudal, +5 kb from the end of the 3’ UTR. (C) Genome-wide distribution of
unmethylated regions (UMRs) and lowly methylated regions (LMRs) in young human β-cells. Pie
chart on the left shows the genomic distribution of regions analyzed.

The total numbers of

regions identified are listed below each pie chart. Averages were calculated for each genomic
region across the three young samples. The color legend is the same as in (B). (D) Genomewide distribution of UMRs and LMRs in old β-cells. Data displayed as in (C).
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Figure 2.2. The DNA methylome is dynamic with aging in the human β-cell. (A) Comparison
of DNA methylation between young and old human β-cells at differentially methylated regions
(DMRs). Slightly more regions lose methylation with age (N=588) than gain methylation with age
(N=494), and the magnitude of changes is greater in regions that lose methylation with age. (B)
Genomic distribution of DMRs that gain or lose methylation with age, in comparison to all DMRs.
(C) Violin plots illustrating the magnitude and direction of changes in DNA methylation that occur
at each DMR, grouped by genomic region. (D) Hierarchical clustering analysis depicting the
methylation state in each DMR for seven WGBS samples. The extreme old and young samples
are most similar to each other, while the 18 year-old sample shows an intermediate pattern.
Donor age is indicated at the bottom of the heatmap.
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Figure 2.3. Differentially methylated regions occur preferentially at islet regulatory
elements. DNA methylome data were compared to whole islet regulatory regions, as defined by
Pasquali and colleagues (Pasquali et al. 2014).
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Regions were defined as: C1, promoters; C2,

inactive enhancers; C3, active enhancers; C4, CTCF-bound sites; C5, other. (A-D) Comparison
of all UMRs and LMRs (potential regulatory regions) to whole islet regulatory regions.

(A)

Hierarchical clustering analysis of percent CpG methylation of β-cell UMRs and LMRs that
overlap with promoter (C1) regions. Sample donor ages are displayed at the bottom of the
heatmap.

Promoter (C1) regions are largely unmethlyated across all ages.

ranges from 0-20% CpG methylation.

Note the scale

(B) Hierarchical clustering analysis of UMR and LMR

overlap with inactive enhancer (C2) regions. Data displayed as in (B) except that the scale
ranges from 0-70%. (C) Hierarchical clustering analysis of UMR and LMR overlap with active
enhancer (C3) regions. Data displayed as in (B). (D) Percentage overlap of C1-C5 regions with
-10

UMRs and LMRs as compared to random genomic background (BG). (***p-value < 10 , chisquare test).

(E-G) Comparison of significant differentially methylated regions to whole islet

regulatory regions. (E) Pie charts of DMRs that gain or lose methylation with age illustrating the
fraction of overlap with each whole islet regulatory region. (F) Table displaying the number of
DMRs that lost or gained methylation with age that overlap with each regulatory region. Note the
most prominent group is active enhancer (C3) regions that lose methylation with age.

(G)

Comparison of percentage of DMRs that lose or gain methylation with age for C1-C3 regions.
Active enhancers (C3) significantly tend to lose methylation with age, while inactive enhancers
-3

(C2) significantly tend to gain methylation with age. (*p-value < 0.05; **p-value < 10 ; ***p-value
-10

< 10 , chi-square test).
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Figure 2.4. Gene expression changes with age in the human β-cell. Hierarchical clustering
analysis of genes that displayed significant changes in expression in either linear or log-linear
fashion as a function of age in human β-cells. See methods section for detailed description of
regression analyses. Donor ages are indicated at the bottom, and the number of genes in each
category is listed in parentheses. Samples in blue font are technical replicates prepared with two
different RNA-Seq kits. In instances where genes significantly changed in both linear and loglinear manners, the gene was included in the model for which the p-value was lower. (p-value <
0.01).
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Figure 2.5. Expression of cell cycle regulators and β-cell transcription factors change with
age in opposite directions. (A) Plots displaying expression as a function of age for two cell
cycle regulators, CDKN2A (p16) and CDKN2C (p18) that are significantly increased with age.
CDKN2A (p16) increases linearly with age, while CDKN2C (p18) increases in a log-linear manner
(p-value < 0.01). FPKM, fragments per kilobase of transcript per million mapped reads. (B) Plots
displayed as in (A) for β-cell-specific transcription factors that decrease in expression with a
function of age. HNF4α and ISL1 decrease in a log-linear manner, while PDX1 decreases in a
linear manner.
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CHAPTER 3 - TALE-mediated epigenetic suppression of CDKN2A increases
replication in human fibroblasts

Adapted from published work:
Bernstein DL, Le Lay JE, Ruano EG, Kaestner KH. TALE-mediated epigenetic
suppression of CDKN2A increases replication in human fibroblasts. J Clin Invest. 2015
May;125(5):1998-2006.
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Abstract
Current epigenetic therapeutics target ubiquitously expressed epigenetic regulators,
meaning that controlling specific genes in selected cell types is impossible. Thus, there is an
overwhelming need to develop tools for targeted epigenetic modifications, and strategies to more
efficiently correct aberrant gene expression in disease. Towards this goal, we have developed a
novel methodology for directing DNA methylation to specific gene loci by conjugating catalytic
domains of DNA methyltransferases (DNMTs) to engineered transcription activator-like effectors
(TALEs). We demonstrate that these TALE-DNMTs direct DNA methylation specifically to the
targeted gene locus in human cells. Further, we show that minimizing direct nucleotide sequence
repeats within the TALE moiety permits efficient lentivirus transduction, and thus easy targeting of
primary cell types. Finally, we demonstrate that directed DNA methylation of the CDNK2A locus,
encoding the cyclin-dependent kinase inhibitor p16, results in decreased CDKN2A expression
and increased replication of primary human fibroblasts, as intended. This phenotypic change of
the cells was reversed by overexpression of p16 cDNA, demonstrating the specificity of our
epigenetic targeting. This improved technology will greatly expand the potential application of
locus-specific epigenetic therapeutics.
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Introduction
Epigenetic modifications are a major determinant of gene expression programs, and
inappropriate changes in these modifications can lead to a wide spectrum of diseases. Cancer is
perhaps the most widely recognized disease area associated with aberrant epigenetic changes,
and more recently epigenetic changes have been implicated in neurological, metabolic, and
cardiovascular diseases (Heerboth et al. 2014). These modifications are known to be reversible,
making them attractive drug targets. To date, clinicians have relied exclusively on general
inhibitors of globally expressed epigenetic regulators, which are responsible for maintaining
integrity of the entire genome (Cacabelos 2014). Thus, unintended effects of such epigenetic
inhibitors may be particularly pervasive and deleterious. Therefore, there is a need for novel tools
for interrogating specific epigenetic changes in the laboratory to enable novel therapeutic
strategies.
DNA methylation has emerged as an important mechanism governing cellular
reprogramming processes such as cell differentiation, cellular senescence, and disease.

In

mammalian cells, DNA methylation is most abundant on cytosine residues in the context of
cytosine guanine dinucleotides, or CpG’s, and when occurring at enhancers and promoters, is
frequently associated with gene repression (Jones 2012).

DNA methylation patterns are

established by the de novo DNA methyltransferases, DNMT3a and DNMT3b, and propagated
across cell divisions by the maintenance DNA methyltransferase, DNMT1 (Bergman and Cedar
2013; Sheaffer et al. 2014).
In an experimental or therapeutic setting, targeted de novo DNA methylation may be
accomplished by tethering the catalytic domain of a DNA methyltransferase (DNMT) to DNA
binding proteins designed to bind specific gene loci, thereby affecting gene expression. Siddique
and colleagues have pioneered this strategy by fusing DNMT catalytic subunits to an artificial zinc
finger protein targeting the promoter of vascular endothelial cell growth factor A (VEGF-A) in a
human cancer cell line, SOKV3 (Siddique et al. 2013). However, challenges in designing artificial
zinc fingers have limited the widespread use of this technology (Bogdanove and Voytas 2011).
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Transcription activator-like effectors (TALEs) are a newer technology that is extremely modular,
easy to assemble, and therefore a more efficient choice for targeted epigenome editing.
The potential for implementing TALEs to direct targeted epigenetic modifications has
become increasingly recognized, as shown in recent studies targeting DNA and histone
demethylation (Maeder et al. 2013; Mendenhall et al. 2013). However, this approach has not yet
been used to repress gene expression by targeted DNA methylation. A key hurdle in widespread
use of TALEs is that they are incompatible with lentivirus technology, a common approach in
stable transmission of genes into host genomes, particularly with primary cells.

The highly

repetitive sequences of the TALE modules have a strong tendency to recombine, and we
addressed this issue by reengineering the TALE repeat moieties to minimize direct DNA repeats
without altering the coding sequence (Holkers et al. 2013).
Our primary target for development of this novel “TALE-DNMT” strategy was the cell
cycle inhibitor, p16, which is encoded by the CDKN2A gene (Figure 3.1A). p16 is a universal
regulator of cellular senescence, and CDKN2A was found to be the most common locus
associated with age-related disease in a meta-analysis of GWAS conducted by Jeck and
colleagues (Martin et al. 2014; Jeck et al. 2012). Prior studies have shown that CDKN2A is
regulated by DNA methylation, and decreasing p16 levels might aid in coaxing terminally
differentiated cells back into the cell cycle, allowing for cell expansion for experimental or cell
therapy uses (Herman et al. 1995; Krishnamurthy et al. 2006).
Thus, we sought to target DNA methylation to the p16 (CDKN2A) locus using lentiviral
delivery of TALE-DNMT fusion proteins to repress gene expression and thereby increase cellular
proliferation. We also characterized the specificity of TALE-mediated epigenetic modifications,
which to date has not been reported. Here, we show that epigenetic targeting of a single locus
can indeed alter its gene expression and cellular functions without appreciable “off target” effects,
thus demonstrating that the phenotype of primary human cells can be altered using epigenetic
tools.
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Results
Custom TALE-DNMT fusion proteins direct DNA methylation to target loci
Sanjana and colleagues have described a protocol for assembly of custom TALEs using
monomer templates and TALE cloning backbones (Sanjana et al. 2012). We modified these
TALE constructs by conjugating a DNA methyltransferase catalytic subunit consisting of the Ctermini of DNMT3a and DNMT3L to the C-terminus of the TALE protein (Siddique et al. 2013).
The cloning backbone contains eGFP and was further modified to include a 3x Flag-tag, which
we employed for cell sorting and protein detection, respectively.

We also constructed a

catalytically inactive TALE-DNMT as a negative control by introducing a point mutation in the
DNMT3a subunit at the E752A position (Rivenbark et al. 2012). TALE monomers were
assembled into the backbone-cloning vector through a series of Golden Gate digestion-ligation
reactions (Sanjana et al. 2012). Following this protocol, we constructed TALE-DNMTs targeting
24-base pair sequences within the CDKN2A promoter (Kent et al. 2002).
illustrated

in

Figure

3.1B

is

engineered

to

bind

the

target

The TALE-DNMT
sequence

5’-

CCTCCTTCCTTGCCAACGCTGGCT-3’, at position -28 to -4 upstream of the p16 (CDKN2A)
transcription start site.
To test our strategy, we transfected HeLa cells, a human cervical adenocarcinoma cell
line, with p16 TALE-DNMT wild-type and mutant expression constructs and compared DNA
methylation of the CDKN2A locus between the two transfected populations, and also to untreated
HeLa cells. Cells were collected 48 hours post-transfection, and FACS-sorted for GFP to isolate
transfected populations. Average transfection efficiency was 12.1% and 14.6% for the wild-type
and mutant constructs, respectively.

DNA methylation was then evaluated using bisulfite

conversion of genomic DNA followed by PCR amplification and high throughput sequencing.
Strikingly, we found that transfection of a single TALE-DNMT construct is sufficient to dramatically
alter DNA methylation across the entire CpG island within the CDKN2A promoter (Figure 3.1C).
DNA methylation was significantly elevated in the p16 TALE-DNMT GFP positive cells compared
to both mutant GFP positive and untreated cells (P < 0.0001). On average, DNA methylation
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increased by 17% across the entire CpG island, and by as much as 66.5% at individual CpGs
when comparing wild-type and mutant transfected populations (Figure 3.1C).

There was no

difference between p16 TALE-DNMT mutant transfected and untreated populations, confirming
that the E752A mutation completely eliminates the catalytic activity of the enzyme.
Despite the dramatic increase in DNA methylation at the CDKN2A promoter, p16
expression decreased by only a small amount in p16 TALE-DNMT wild-type transfected HeLa
cells compared to mutant and uninfected populations (data not shown). This is likely due to the
fact that p16 expression is often upregulated in cervical cancers, and may be subject to aberrant
regulatory mechanisms in these transformed cells (Ivanova et al. 2007; McLaughlin-Drubin et al.
2013). Thus, we hypothesized that a primary human cell line might be a more suitable system to
study functionality at this particular target.

Minimizing direct repeats in TALE modules permits lentiviral delivery
We next considered alternate strategies for gene delivery that might be more suitable to
targeting primary human cells, which are often difficult to transfect even ex vivo.

Lentiviral

vectors provide an efficient method for stably introducing genes into host genomes of multiple cell
types. However, standard TALE technology is incompatible with lentiviral delivery due to the
large number of tandem repeats in the TALE moiety that lead to sequence loss by DNA
recombination (Holkers et al. 2013). In order to promote efficient integration of intact TALEs into
host genomes using lentivirus, we utilized the degeneracy of the genetic code to minimize direct
repeats across the TALE DNA binding domain to build “jumbled” TALE-DNMTs (jTALE-DNMTs),
similar to the strategy pursued by Yang and colleagues (Yang et al. 2013). Furthermore, in order
to accommodate the size limitation of the lentiviral genome, we made several modifications to the
TALE-DNMT constructs by decreasing the number of repeats from 24 to 18, such that the revised
TALE targets the sequence 5’-TCCTTGCCAACGCTGGCT-3’. We also truncated the promoter
and removed the eGFP sequence.
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We prepared lentivirus for wild-type and mutant p16 jTALE-DNMT constructs and tested
their functionality in HeLa cells. Western blots confirmed that full-length jTALE-DNMT protein
was indeed produced following infection (Figure 3.2A). In order to demonstrate that the entire,
un-recombined jumbled TALE repeat moiety was integrated into the host genome, we PCRamplified the repeat region from genomic DNA of transduced cells. We also amplified the jTALE
repeat region from cDNA to determine that the full-length repeat region was transcribed (Figure
3.2B).

Together, these assays confirmed integration and expression of full-length TALE

constructs. We then established that p16 jTALE-DNMT lentiviruses target CpG methylation at the
CDKN2A locus, with an average increase of 13.8% in the p16 jTALE-DNMT infected population
compared to the mutant (Figure 3.2C). The lesser extent of DNA methylation in the lentivirus
infections compared to transfected cells is likely due to the fact that cells could not be sorted into
infected populations. These data demonstrate convincingly that jumbled TALE repeats can be
administered stably using lentiviral vectors, removing a significant obstacle for wide-spread
application of the TALE technology.

Targeted DNA methylation in primary human cells results in decreased gene expression of
the target gene
Having successfully developed jTALE-DNMTs for lentiviral delivery, we next tested if
TALE-DNMTs can methylate the p16 (CDKN2A) locus in primary human fibroblasts.

After

infection with wild-type and mutant p16 jTALE-DNMT constructs, DNA methylation was again
evaluated by sodium bisulfite conversion followed by PCR amplification and high throughput
sequencing. Average DNA methylation was significantly increased by approximately 10% across
the CDKN2A CpG island when comparing fibroblasts infected with wild-type and mutant p16
jTALE-DNMTs (P < 0.005), with several CpGs showing increases in methylation of 30 to 50%
(Figure 3.3A). To evaluate the functional consequence of increased CpG methylation at this
locus, we measured p16 mRNA levels and found an approximately 50% decrease in p16 mRNA
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levels in p16 jTALE-DNMT infected fibroblasts relative to mutant infected fibroblasts (P < 0.05)
(Figure 3.3B).
To further characterize the effects of the p16 TALE-DNMT locally and genome-wide, we
measured DNA methylation at the two other CpG islands within the p16 (CDKN2A) locus, and at
β-actin, a housekeeping gene located on a different chromosome (Figure 3.3C). Interestingly, we
found that the effect of the TALE-DNMT on average DNA methylation decreased with distance
from the transcription start site at the p16 (CDKN2A) locus, as DNA methylation increased
significantly by 6% at CGI2, but not significantly at CGI3. The β-actin locus on chromosome 7
was completely unaffected.
Given the increase in DNA methylation observed at the adjacent CpG island, we
considered the possibility that other nearby genes might display altered levels of DNA methylation
(Figure 3.3D). Indeed, we measured increased methylation in several genes adjacent to p16
(CDKN2A), including p14ARF, another transcript within the CDKN2A locus, CDKN2B, and MTAP.
No changes were observed in IFNE.

We next measured mRNA levels at these genes to

determine the functional consequence of the increased DNA methylation and observed no
changes in the mRNA levels of CDKN2B, or MTAP and IFNE (Figure 3.3E). We also analyzed
expression of the three other transcripts at the CDKN2A locus and did not observe a significant
change in expression of p14ARF (Figure 3.3E), while p12 and p16γ, were not detectable by
qPCR in human fibroblasts.
In order to validate the broad applicability of the TALE-DNMT strategy, we also tested the
p16 TALE-DNMT lentiviruses in primary human coronary artery smooth muscle cells (hCASMCs),
and showed that p16 jTALE-DNMT wild-type infected cells had increased DNA methylation and a
corresponding decrease in p16 (CDKN2A) expression compared to mutant infected cells (Figure
3.4). As further validation of our strategy we also designed a new p16 TALE-DNMT targeted to
the p16 (CDKN2A) promoter 118 to 136 base pairs upstream from the transcription start site (5’TAACAGAGTGAACGCACT-3’).

This additional TALE-DNMT, p16 TALE-DNMT.2, also

increased DNA methylation and led to even stronger repression of p16 transcription when
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comparing wild-type and mutant infected cells (Figure 3.5).

Remarkably, this stronger gene

repression was associated with fewer affected CpGs, suggesting that specific CpGs are more
relevant than others.

In sum, the overall TALE-DNMT strategy can be extended to multiple

primary human cell types and multiple target DNA binding sites.

DNA methylation of the p16 (CDKN2A) locus results in increased replication in primary
human cells
Our goal in decreasing p16 expression is to more readily permit entry into the cell cycle.
Therefore, we next evaluated rates of DNA replication in primary human fibroblasts infected with
wild-type and mutant p16 jTALE-DNMTs. Following infection and subsequent incubation for 72
hours, we measured incorporation of the thymidine analogue 5-ethynyl-2’-deoxyuridine (EdU) by
immunofluorescence staining after a 60-minute incubation period. p16 jTALE-DNMTs increased
DNA replication by nearly two-fold in the wild-type compared to mutant infected populations
(Figures 3.6A and 3.6B). In order to confirm that the altered proliferation observed in p16 jTALEDNMT-transduced human fibroblasts was specifically due to suppression of p16 transcription,
and not some unknown off-target effect, we restored p16 levels by co-infection with a lentivirus
driving p16 expression under control of the CMV promoter. As shown in Figure 3.6B, reexpression of p16 completely ablated the pro-proliferative effect of p16 jTALE-DNMT activity,
providing strong evidence that increased replication in human fibroblasts was indeed caused by
reduced p16 levels. Since p16 mediates progression through the G1 phase of the cell cycle, we
also wanted to confirm that increased DNA replication rates translated into cellular proliferation.
We therefore calculated population-doubling time of infected human fibroblasts and found that
this was reduced by 10% in the p16 jTALE-DNMT wild-type infected cells compared to mutant
(Figure 3.6C).
To further eliminate the possibility that increased proliferation of epigenetically targeted
human fibroblasts might be impacted by other cell cycle regulators, we determined the expression
levels of a panel of cyclin-dependent kinase inhibitors, cyclin-dependent kinases and other
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molecules related to the p16 inhibitory pathway. As shown in Figure 3.6D, none of these cell
cycle regulators were affected by p16 jTALE-DNMT infection comparing wild-type and mutant
infected populations, attesting to the specificity of our strategy. Although we demonstrated that
p16 TALE-DNMT infection does not affect expression of other cell cycle regulators, we also
assessed DNA methylation at these loci.

We found that some genes showed increased

methylation while others did not (Figure 3.6E). Since changes across cell cycle regulators are
inconsistent, we cannot say for certain whether or not these changes are a direct consequence of
p16 TALE-DNMT activity, or an indirect consequence of decreased p16 expression and
accelerated proliferation. In summary, targeting DNA methylation to the p16 (CDKN2A) promoter
led to changes in expression exclusively of the p16 transcript, resulting in increased cell
proliferation, without altering the activity of other cell cycle regulator genes.

Discussion
We have demonstrated that customized TALEs can be employed to direct DNA
methylation to specific gene loci, and thereby decrease gene expression. We selected p16 as
our primary target due to its role in mediating cellular senescence with the idea that epigenetic
suppression of p16 might facilitate cell cycle entry in terminally differentiated cells in the context
of regenerative medicine. In developing this novel technology, we employed a primary human
fibroblast cell line that is not transformed, in contrast to the majority of human cells lines, which
are often subject to dysfunctional cell cycle regulation. Importantly, even in this readily dividing
cell population we have shown that increasing DNA methylation at a single cell cycle inhibitor
gene locus is sufficient to increase cellular proliferation. Further, the observed changes in
replication rate were entirely dependent on suppression of the intended gene product, p16. We
have also proven that these targeted epigenetic modifiers can be delivered using lentiviral
vectors, which will dramatically expand the breadth of their application in different biological
systems. We validated our findings of TALE-DNMT mediated targeted DNA methylation and p16
suppression in primary human coronary artery smooth muscle cells, and with an independent
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TALE-DNMT construct targeting the p16 (CDKN2A) locus, attesting to the broad applicability of
this technology. We have shown that the TALE-DNMT strategy is a powerful and robust tool that
can be utilized to change cell fate.
We also found that nearby loci are more likely to be susceptible to off-target effects by
TALE-DNMTs than distal loci, which until now has been an underreported consequence of TALEmediated epigenetic modifiers. These “near-target” effects appear to be distance dependent, and
in our case functionally irrelevant as altered gene expression was detected only at the target
gene, CDKN2A. It is likely that the “near target” effects can be attributed to the three-dimensional
structure of chromatin. Chromatin interactions such as chromatin looping may bring nearby loci
into the vicinity of the TALE-DNMT construct, permitting DNA methylation in the absence of direct
TALE-DNA binding. We also observed small increases in DNA methylation at some but not all
cell cycle inhibitors and other cell cycle regulators implicated in the p16/pRb pathway. Critically,
these changes did not impact gene activity. Nevertheless, future efforts will be directed towards
further improving specificity by strategies such as attenuating DNMT subunit catalytic activity, or
splitting the DNMT domain, similar to the TALEN system, such that two separate TALE fusion
proteins are required for methyltransferase activity.

Also, the TALE-DNMT strategy may be

further optimized through large-scale screens of TALEs to determine if certain target binding sites
are more effective than others.
Here, we demonstrate the utility of TALE-directed DNA methylation as a strategy for
altering the epigenetic state in a targeted, locus-specific fashion. We have amended this strategy
to accommodate lentiviral delivery to primary human cells, and have shown that this system can
be used to alter cellular behavior.

We also shed light on the specificity of TALE-mediated

epigenetic targeting, which is an ongoing area of future investigation. This study may have
widespread implications for investigating gene regulation, and in developing novel therapeutic
strategies for correcting aberrant gene expression in disease.
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Methods
TALE target selection and construction
Twenty-four base pair TALE target sequences within the CDKN2A promoter were
selected using the web-based tool, TAL Effector-Nucleotide Targeter (TALE-NT) 2.0, which
optimizes unique binding sites within a specified target region (Doyle et al. 2012; Cermak et al.
2011). The sequence targeted in the present work was 5’-CCTCCTTCCTTGCCAACGCTGGCT3’. Cloning vectors and TALE repeat monomer plasmids were obtained from the TALE Toolbox
kit (Addgene). pTALETF vectors were modified to replace the VP64 domain with flag-tagged
DNMT3a-3L by cloning. Following target selection, the 24 corresponding monomers were
assembled into a modified TALE backbone containing either the DNMT3a-3L catalytic subunit or
mutant DNMT3a-3L catalytic subunit through a series of golden gate digestion-ligation reactions,
as described by Sanjana and colleagues (Sanjana et al. 2012). The mutant DNMT catalytic
domain contained a catalytically inactive DNMT3a subunit due to a point mutation, E752A
(Rivenbark et al. 2012). The DNMT3a-3L DNA sequence was synthesized by Eurofins MWG
Operon and cloned into the TALE backbone by restriction enzyme digestion followed by ligation.
PCR primers including the E752A point mutation were used to amplify a DNA fragment from the
TALE-DNMT plasmid containing the point mutation, and the fragment was subsequently cloned
into the TALE-DNMT backbone by restriction enzyme digestion followed by ligation to generate
the mutant construct.
Forward:

The point mutation is underlined in the reverse primer (PCR primers,

5’-CAAGCCCCAAGAAGAAGAGA-3’

and

Reverse:

5’-

CCCATGGCCACCACATTGGCAAAGAG-3’). The complete coding sequence of the p16 TALEDNMT is provided in Figure 3.7.

Jumbled TALE lentivirus design and construction
Jumbled TALEs were designed by disrupting direct repeats greater than eleven
nucleotides utilizing the degeneracy of the genetic code to change DNA sequence without
altering protein coding sequence. In order to accommodate the size limitation of the lentiviral
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genome, the TALE target sequence was decreased to 18 bases instead of 24, a minimal CMV
promoter was used, and eGFP was removed. The 18 base pair sequence targeted with the
jumbled TALE was 5’-TCCTTGCCAACGCTGGCT-3’.

Series of plasmids containing jumbled

sequences for 6 monomers were ordered from Eurofins MWG Operon with appropriate restriction
sites such that these hexamers could be incorporated into the protocol described by Sanjana and
colleagues at a Golden-Gate digestion-ligation step. TALE-DNMT constructs were then cloned
into a lentiviral vector obtained from The Wistar Institute Protein Expression Core (Philadelphia,
PA).

Lentiviruses were also prepared by The Wistar Institute Protein Expression Core

(Philadelphia, PA). The coding sequence for the jumbled p16 TALE repeat domain is provided in
Figure 3.8.

Transfection of HeLa cells
6

HeLa cells (American Type Culture Collection) were seeded at a density of 5x10 cells
3

per 10cm .

After 24 hours, cells were transfected with 12.5µg of plasmid DNA using
TM

Lipofectamine® 2000 reagent (Life Technologies ) according to manufacturer's protocol. Fortyeight hours post-transfection, cells were trypsinized with 0.25% trypsin + EDTA and dispersed for
FACS sorting for GFP. FACS sorting was performed by the Flow Cytometry and Cell Sorting
Resource Laboratory (FCCSRL) at the University of Pennsylvania (Philadelphia, PA). Sorted
populations were harvested using the Qiagen AllPrep DNA/RNA Mini Kit.

DNA methylation analysis
Genomic DNA was bisulfite-converted using the Qiagen EpiTect Bisulfite Kit (Qiagen
GmbH) and target loci were PCR amplified using the PyroMark PCR Kit (Qiagen GmbH). Four
primer pairs were designed to PCR amplify across the entire CDKN2A CpG island within the
promoter region.

Additional primer pairs were also designed to amplify regions within each

control locus. Primers were designed to amplify approximately 250-300 base pair regions at the
CpG island closest to the transcription start site of each gene. In instances when no CpG island
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was present, a sequence within the gene promoter was chosen.

All primer sequences and

genomic coordinates for each amplicon are listed in Table 3.1. Pyromark PCR reactions were
carried out per manufacturer’s instructions. DNA sequencing libraries were prepared with the
automated Ovation® SP+ Ultralow DR Multiplex System (NuGEN Technologies Inc.) and
subsequently sequenced on an Illumina MiSeq with 150 base pair paired-end reads.

DNA

sequences were aligned to an in silico bisulfite converted human genome using the BS Seeker
program and analyzed by the Next Generation Sequencing Core at the University of
Pennsylvania (Philadelphia, PA) (Chen et al. 2010). Only CpGs with sequence coverage greater
than 1000 reads were considered. Average DNA methylation across regions was analyzed by
one-way ANOVA with Tukey’s correction for multiple comparisons when comparing more than
two groups, and by a two-tailed t-test when comparing two groups.

Individual CpGs were

compared by multiple t-tests (P < 0.05). All next-generation sequencing data was deposited to
the Gene Expression Omnibus (GEO) public database according to MINSEQE-standards
(accession# GSE66456).

Quantitative real-time PCR for gene expression
To assess mRNA levels, RNA extracted with the Qiagen AllPrep DNA/RNA Mini Kit was
TM

reverse-transcribed using SuperScript® II Reverse Transcriptase (Life Technologies ) to
synthesize cDNA. qRT-PCR was performed on the Agilent Technologies Strategene Mx3000P
using 2x Brilliant III SYBR® Green qPCR master mix plus ROX reference dye (Agilent
Technologies). Thermal profiles were set according to manufacturer’s protocol. mRNA levels
were normalized to HPRT1. qPCR primer sequences are listed in Table 3.2. Differences in
mRNA levels were compared by two-tailed t-tests (P < 0.05).

PCR assay
To demonstrate integration and transcription of full-length TALE DNA in lentiviral
infections of HeLa cells, the TALE repeat moiety was amplified from genomic DNA and cDNA,
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respectively, with Herculase II Fusion DNA polymerase. (TALE repeat primers, Forward: 5’CCAGTTGCTGAAGATCGCGAAGC-3’ and Reverse: 5’-TGCCACTCGATGTGATGTCCTC-3’).
The Woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) present in lentiviral
constructs was used as a control (Forward: 5’-AGCGTCGACAATCAACCTCT-3’ and Reverse: 5’GGCATTAAAGCAGCGTATCC-3’).

PCR products were purified using the QIAquick® PCR

Purification Kit (Qiagen GmbH), and 100ng of each product was run on a 0.8% agarose gel.

HeLa cell lentivirus transduction
6

3

HeLa cells were seeded at a density of 1X10 cells per 10cm in DMEM culture medium
supplemented with 10% fetal bovine serum and penicillin/streptomycin. Twenty-four hours post7

seeding, cells were treated with 1X10 titration units of lentivirus. Polybrene was added at a
concentration of 8ng/µl to enhance viral infection. Cells were harvested four days post-infection
for either DNA/RNA extraction or preparation of protein lysate as described.

Western blotting
Following transduction, cells were sedimented and homogenized in RIPA buffer. Cell
lysates were sonicated, sedimented to remove cellular debris, and protein concentration was
measured by the Millipore Direct Detect system. 50µg of protein lysate was denatured with DTT
TM

and separated by size on a NuPAGE 4-12% Bis-Tris gel (Life Technologies ). Samples were
TM

transferred onto a PVDF membrane (Novex by Life Technologies ) and blocked with PBST 5%
non-fat dry milk. Membranes were incubated with anti-flag antibody (F1804-200UG monoclonal
ANTI-FLAG® M2 antibody, SIGMA Life Sciences) and anti-β-actin antibody (β-actin antibody
#4967, Cell Signaling Technology, Inc.), and then with HRP-conjugated secondary antibodies (sc2030 Goat anti-rabbit IgG-HRP and sc-2005 goat anti-mouse IgG-HRP, Santa Cruz
Biotechnology). Blots were developed using ECL
(GE Healthcare).
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TM

Prime Western Blotting Detection Reagent

Primary human fibroblast transduction
Primary human foreskin fibroblasts purchased from ATCC, CCD-1112Sk (ATCC® CRL2429™), were seeded at a density of 1X10

6

cells per 10cm

3

in IMDM culture medium

supplemented with 10% fetal bovine serum and penicillin/streptomycin. After 24 hours cells were
infected with 1X10

7

titration units of lentivirus in complete medium with polybrene at a

concentration of 8ng/µl and harvested 4 days later using the Qiagen AllPrep DNA/RNA Mini Kit.

Primary human coronary artery smooth muscle cell (hCASMC) transduction
Primary hCASMCs were purchased from Lonza (CC-2583) and plated in 6-well plates at
a density of 75,000 cells per well in culture media prepared from the Lonza Clonetics
2 BulletKit

TM

TM

TM

SmGM -

(CC-3182). After 24 hours in culture, cells were infected with lentivirus as described

for human fibroblasts.

EdU Incorporation
Primary human fibroblasts were plated in 8-well chamber slides and infected with either
p16 jTALE-DNMT WT or Mut lentivirus as described above. After 72 hours in culture, cells were
incubated with 5-ethynyl-2’-deoxyuridine (EdU) for 1 hour. EdU incorporation was visualized by
immunofluorescence staining using the Click-iT® Plus EdU Imaging Kit, Alexa Fluor® 555 picolyl
TM

azide (Molecular Probes® by Life Technologies ). Percent EdU incorporation was calculated as
the number of EdU positive cells divided by the total number of cells (n=7).

Differences in

percent EdU incorporation were compared in a two-tailed t-test (P < 0.05).

p16 re-expression
For p16 re-expression experiments, a lentiviral vector incorporating the human p16 cDNA
clone under a CMV promoter was purchased from OriGene Technologies, Inc. (Catalog No.
RC220937L1).

Lentivirus was prepared by the Wistar Institute Protein Expression Core

(Philadelphia, PA). In separate EdU Incorporation experiments, CMV-p16 lentivirus was added in
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combination with either p16 jTALE-DNMT WT or Mut lentivirus. Titers for CMV-p16 lentivirus
6

were reduced to approximately 1X10 titration units per 1 million cells. Percent EdU incorporation
was calculated as the number of EdU positive cells divided by the total number of cells (n=4).
Differences in percent EdU incorporation were compared in a two-tailed t-test.

Population Doubling Time Assay
Human fibroblasts were infected as described above, except that a lower seeding density
5

3

of 4X10 cells per 10cm plate was used to prevent contact growth inhibition during the 4 day
infection period. Cells were counted prior to plating and at the end of the experiment. Population
doubling time (DT) as described by ATCC was calculated as DT = Tln2/ln(Xf/Xi) where T is
incubation time (days), Xi is initial cell number and Xf is final cell number.

Statistics
Data is displayed as mean ± SEM, and at least three replicates were conducted for each
experiment.

Data was assessed by one-way ANOVA with Tukey’s correction for multiple

comparisons or by two-tailed t-test, as appropriate. Significance was defined as P < 0.05.

Study Approval
All experiments were performed in accordance with guidelines set forth by the University
of Pennsylvania. Study approval was not required since no animals were used and primary
human tissues were obtained from commercially available sources.
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Figure 3.1. Targeted CpG methylation of the p16 (CDKN2A) locus using TALE-DNMT fusion
proteins. (A) TALE-DNMT strategy for altering the epigenetic state of the p16 (CDKN2A)
promoter. Locus-specific TALEs were fused to the catalytic domain of DNA methyltransferase
(p16 TALE-DNMT), or a catalytically inactive DNA methyltransferase with the point mutation
E752A (p16 TALE-DNMT Mut). (B) Detailed diagram of TALE-DNMT construct and target site in
the p16 (CDKN2A) locus. Black boxes indicate the three exons of the p16 transcript, and green
boxes indicate CpG islands. The TALE-DNMT was targeted to the CpG island at the promoter
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just before the transcription start site. Legend on the right side of the diagram indicates which
nucleotide is targeted by each of the four different TALE repeat monomers, which are colorcoded. (C) Percent methylation of individual CpGs within the CDKN2A promoter in FACS-sorted
GFP-positive populations compared to untreated HeLa cells. HeLa cells were transfected with the
p16 TALE-DNMT wild-type or p16 TALE-DNMT mutant construct and cultured for 48 hours. Cells
were then FACS sorted for GFP to isolate transfected populations. DNA methylation was
quantified by sequencing of PCR-amplified bisulfite-converted genomic DNA.

Graphs reflect

percent DNA methylation at each CpG and its position relative to the transcription start site (mean
± SEM; n = 3). Diagram below the graph illustrates the region of the p16 (CDKN2A) promoter
that was analyzed. Data points outlined in black are significantly elevated in the p16 TALEDNMT population compared to the p16 TALE-DNMT mutant population (P < 0.05, multiple ttests).
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Figure 3.2. Minimizing direct repeats permits lentiviral expression of TALE fusion proteins.
HeLa cells were infected with p16 jumbled TALE-DNMT, p16 jumbled TALE-DNMT mutant, or
GFP control lentiviruses and harvested after four days. (A) Western blot of HeLa cells infected
with p16 jTALE-DNMT or p16 jTALE-DNMT mutant lentivirus showing production of the full-length
protein. (B) PCR amplification of the full-length TALE repeat moiety from genomic DNA (gDNA),
demonstrating integration of the intact construct into the host genome, and from cDNA,
demonstrating transcription of full length mRNA, in infected HeLa cells. Amplification of plasmid
DNA is shown as a reference. jTALE, jumbled TALE;
posttranscriptional regulatory element.

WPRE, Woodchuck hepatitis virus

(C) Percent DNA methylation of the p16 (CDKN2A)

locus in HeLa cells infected with p16 jTALE-DNMT wild-type and p16 jTALE-DNMT mutant
lentivirus (mean ± SEM; n = 3). Data points outlined in black indicate CpGs in which DNA
methylation is significantly elevated in p16 jTALE-DNMT wild-type infected cells compared to p16
jTALE-DNMT mutant infected cells (P < 0.05, multiple t-tests).
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Figure 3.3. Targeted CpG methylation at the p16 (CDKN2A) locus results in decreased
gene expression in primary human cells. Primary human fibroblasts were transduced with p16
jTALE-DNMT wild-type or p16 jTALE-DNMT mutant lentiviruses and incubated for four days. (A)
Percent DNA methylation of CpGs within the p16 (CDKN2A) promoter region. Graphs reflect
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percent DNA methylation at each CpG (mean ± SEM; n = 3) and position relative to the
transcription start site. Data points outlined in black are significantly elevated in the p16 jTALEDNMT population compared to the p16 jTALE-DNMT mutant population. P < 0.05, multiple ttests. (B) p16 transcript expression in fibroblasts treated with p16 jTALE-DNMT wild-type or
mutant lentiviruses relative to the mutant negative control. Expression levels were normalized to
HPRT1 mRNA levels (mean ± SEM; n = 3). *, P < 0.05, two-tailed t-test. (C) Average percent
DNA methylation of CpGs at each CpG island within the p16 (CDKN2A) locus and at β-actin
(ACTB), a housekeeping gene located on a different chromosome. The diagram below the graph
illustrates the position of CpG islands at the p16 (CDKN2A) locus. (mean ± SEM; n = 3). *, P <
0.05; **, P < 0.01, two-tailed t-test. (D) Average percent methylation at genes adjacent to p16
(CDKN2A), as described in (C). The diagram above the graph indicates the position of each gene
relative to p16 (CDKN2A). (E) mRNA expression of genes adjacent to p16 (CDKN2A) in
lentivirally-transduced human fibroblasts, determined as described in (B).
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Figure 3.4. p16 TALE-DNMT strategy can be employed in primary human coronary artery
smooth muscle cells to decrease p16 expression. Primary human coronary artery smooth
muscle cells (hCASMCs) were infected with p16 jTALE-DNMT wild-type or mutant lentivirus.
After 4 days of infection, cells were harvested and assessed for DNA methylation (A), and p16
(CDKN2A) expression (B) as described in the main text.
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Figure 3.5. Multiple p16 TALE-DNMT constructs can be designed to decrease p16
expression. An additional TALE-DNMT (p16 jTALE-DNMT.2) was designed to target the p16
(CDKN2A) promoter region 118 to 139 base pairs upstream of the transcription start site. Wildtype and mutant infected with p16 jTALE-DNMT.2 were evaluated for DNA methylation (A) and
p16 (CDKN2A) gene expression (B) as described in prior human fibroblast experiments.
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Figure 3.6. Alterations in p16 levels due to p16 TALE-DNMT results in increased
proliferation in primary human cells. (A) Representative immunofluorescence image of EdU
incorporation in human fibroblasts infected with wild-type or mutant p16 jTALE-DNMT lentivirus.
After 72 hours infection, cells were incubated with EdU for 1 hour and stained for EdU. Cell
nuclei are stained blue (DAPI) and EdU positive nuclei are stained red. Images were taken at 10X
magnification (n=7). (B) Percent EdU incorporation of cells infected with p16 jTALE-DNMT wild-
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type or mutant lentivirus, with (n = 4) or without (n = 7) co-infection of CMV-p16 lentivirus. Three
random images were counted for each biological replicate (mean ± SEM). ***, P < 0.001; n.s.,
not significant, two-tailed t-test. (C) Population doubling time of human fibroblasts infected with
p16 jTALE-DNMT wild-type or mutant lentivirus. (mean ± SEM; n = 4). *, P < 0.05, two-tailed ttest. (D) Transcript levels of cell cycle regulators in human fibroblasts transduced with wild-type
p16 jTALE-DNMT lentivirus relative to mutant lentivirus. Expression was normalized to HPRT1
mRNA levels (mean ± SEM; n = 3). Two-tailed t-test. (E) Average percent DNA methylation of
CpGs at the nearest CpG island of cell cycle regulators evaluated in (D).

Average DNA

methylation was measured by PCR amplification of bisulfite converted genomic DNA followed by
high-throughput sequencing (mean ± SEM; n = 3). **, P < 0.01; ***, P < 0.001, two-tailed t-test.
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Figure 3.7. Coding sequence of p16 TALE-DNMT3a-3L.

ATGTCGCGGACCCGGCTCCCTTCCCCACCCGCACCCAGCCCAGCGTTTTCGGCCGACTCGTTCTCAGACCT
GCTTAGGCAGTTCGACCCCTCACTGTTTAACACATCGTTGTTCGACTCCCTTCCTCCGTTTGGGGCGCACC
ATACGGAGGCGGCCACCGGGGAGTGGGATGAGGTGCAGTCGGGATTGAGAGCTGCGGATGCACCACCCCCA
ACCATGCGGGTGGCCGTCACCGCTGCCCGACCGCCGAGGGCGAAGCCCGCACCAAGGCGGAGGGCAGCGCA
ACCGTCCGACGCAAGCCCCGCAGCGCAAGTAGATTTGAGAACTTTGGGATATTCACAGCAGCAGCAGGAAA
AGATCAAGCCCAAAGTGAGGTCGACAGTCGCGCAGCATCACGAAGCGCTGGTGGGTCATGGGTTTACACAT
GCCCACATCGTAGCCTTGTCGCAGCACCCTGCAGCCCTTGGCACGGTCGCCGTCAAGTACCAGGACATGAT
TGCGGCGTTGCCGGAAGCCACACATGAGGCGATCGTCGGTGTGGGGAAACAGTGGAGCGGAGCCCGAGCGC
TTGAGGCCCTGTTGACGGTCGCGGGAGAGCTGAGAGGGCCTCCCCTTCAGCTGGACACGGGCCAGTTGCTG
AAGATCGCGAAGCGGGGAGGAGTCACGGCGGTCGAGGCGGTGCACGCGTGGCGCAATGCGCTCACGGGAGC
ACCCCTCAACCTGACCCCAGAGCAGGTCGTGGCAATTGCGAGCCATGACGGGGGAAAGCAGGCACTCGAAA
CCGTCCAGAGGTTGCTGCCTGTGCTGTGCCAAGCGCACGGACTTACGCCAGAGCAGGTCGTGGCAATTGCG
AGCCATGACGGGGGAAAGCAGGCACTCGAAACCGTCCAGAGGTTGCTGCCTGTGCTGTGCCAAGCGCACGG
ACTAACCCCAGAGCAGGTCGTGGCAATTGCGAGCAACGGAGGGGGAAAGCAGGCACTCGAAACCGTCCAGA
GGTTGCTGCCTGTGCTGTGCCAAGCGCACGGGTTGACCCCAGAGCAGGTCGTGGCAATTGCGAGCCATGAC
GGGGGAAAGCAGGCACTCGAAACCGTCCAGAGGTTGCTGCCTGTGCTGTGCCAAGCGCACGGCCTGACCCC
AGAGCAGGTCGTGGCAATTGCGAGCCATGACGGGGGAAAGCAGGCACTCGAAACCGTCCAGAGGTTGCTGC
CTGTGCTGTGCCAAGCGCACGGACTGACACCAGAGCAGGTCGTGGCAATTGCGAGCAACGGAGGGGGAAAG
CAGGCACTCGAAACCGTCCAGAGGTTGCTGCCTGTGCTGTGCCAAGCGCACGGACTTACACCCGAACAAGT
CGTGGCAATTGCGAGCAACGGAGGGGGAAAGCAGGCACTCGAAACCGTCCAGAGGTTGCTGCCTGTGCTGT
GCCAAGCGCACGGACTTACGCCAGAGCAGGTCGTGGCAATTGCGAGCCATGACGGGGGAAAGCAGGCACTC
GAAACCGTCCAGAGGTTGCTGCCTGTGCTGTGCCAAGCGCACGGACTAACCCCAGAGCAGGTCGTGGCAAT
TGCGAGCCATGACGGGGGAAAGCAGGCACTCGAAACCGTCCAGAGGTTGCTGCCTGTGCTGTGCCAAGCGC
ACGGGTTGACCCCAGAGCAGGTCGTGGCAATTGCGAGCAACGGAGGGGGAAAGCAGGCACTCGAAACCGTC
CAGAGGTTGCTGCCTGTGCTGTGCCAAGCGCACGGCCTGACCCCAGAGCAGGTCGTGGCAATTGCGAGCAA
CGGAGGGGGAAAGCAGGCACTCGAAACCGTCCAGAGGTTGCTGCCTGTGCTGTGCCAAGCGCACGGACTGA
CACCAGAGCAGGTCGTGGCAATTGCGAGCAACCACGGGGGAAAGCAGGCACTCGAAACCGTCCAGAGGTTG
CTGCCTGTGCTGTGCCAAGCGCACGGCCTCACCCCAGAGCAGGTCGTGGCAATTGCGAGCCATGACGGGGG
AAAGCAGGCACTCGAAACCGTCCAGAGGTTGCTGCCTGTGCTGTGCCAAGCGCACGGACTTACGCCAGAGC
AGGTCGTGGCAATTGCGAGCCATGACGGGGGAAAGCAGGCACTCGAAACCGTCCAGAGGTTGCTGCCTGTG
CTGTGCCAAGCGCACGGACTAACCCCAGAGCAGGTCGTGGCAATTGCGAGCAACATCGGGGGAAAGCAGGC
ACTCGAAACCGTCCAGAGGTTGCTGCCTGTGCTGTGCCAAGCGCACGGGTTGACCCCAGAGCAGGTCGTGG
CAATTGCGAGCAACATCGGGGGAAAGCAGGCACTCGAAACCGTCCAGAGGTTGCTGCCTGTGCTGTGCCAA
GCGCACGGCCTGACCCCAGAGCAGGTCGTGGCAATTGCGAGCCATGACGGGGGAAAGCAGGCACTCGAAAC
CGTCCAGAGGTTGCTGCCTGTGCTGTGCCAAGCGCACGGACTGACACCAGAGCAGGTCGTGGCAATTGCGA
GCAACCACGGGGGAAAGCAGGCACTCGAAACCGTCCAGAGGTTGCTGCCTGTGTTATGTCAGGCCCATGGG
CTCACCCCAGAGCAGGTCGTGGCAATTGCGAGCCATGACGGGGGAAAGCAGGCACTCGAAACCGTCCAGAG
GTTGCTGCCTGTGCTGTGCCAAGCGCACGGACTTACGCCAGAGCAGGTCGTGGCAATTGCGAGCAACGGAG
GGGGAAAGCAGGCACTCGAAACCGTCCAGAGGTTGCTGCCTGTGCTGTGCCAAGCGCACGGACTAACCCCA
GAGCAGGTCGTGGCAATTGCGAGCAACCACGGGGGAAAGCAGGCACTCGAAACCGTCCAGAGGTTGCTGCC
TGTGCTGTGCCAAGCGCACGGGTTGACCCCAGAGCAGGTCGTGGCAATTGCGAGCAACCACGGGGGAAAGC
AGGCACTCGAAACCGTCCAGAGGTTGCTGCCTGTGCTGTGCCAAGCGCACGGCCTGACCCCAGAGCAGGTC
GTGGCAATTGCGAGCCATGACGGGGGAAAGCAGGCACTCGAAACCGTCCAGAGGTTGCTGCCTGTGCTGTG
CCAAGCGCACGGACTGACACCAGAGCAGGTCGTGGCAATTGCGAGCAACGGAGGGGGAAAGCAGGCACTCG
AAACCGTCCAGAGGTTGCTGCCTGTGCTGTGCCAAGCGCACGGACTCACGCCTGAGCAGGTAGTGGCTATT
GCATCCCATGACGGGGGCAGACCCGCACTGGAGTCAATCGTGGCCCAGCTTTCGAGGCCGGACCCCGCGCT
GGCCGCACTCACTAATGATCATCTTGTAGCGCTGGCCTGCCTCGGCGGACGACCCGCCTTGGATGCGGTGA
AGAAGGGGCTCCCGCACGCGCCTGCATTGATTAAGCGGACCAACAGAAGGATTCCCGAGAGGACATCACAT
CGAGTGGCAGATCACGCGCAAGTGGTCCGCGTGCTCGGATTCTTCCAGTGTCACTCCCACCCCGCACAAGC
GTTCGATGACGCCATGACTCAATTTGGTATGTCGAGACACGGACTGCTGCAGCTCTTTCGTAGAGTCGGTG
TCACAGAACTCGAGGCCCGCTCGGGCACACTGCCTCCCGCCTCCCAGCGGTGGGACAGGATTCTCCAAGCG
AGCGGTATGAAACGCGCGAAGCCTTCACCTACGTCAACTCAGACACCTGACCAGGCGAGCCTTCATGCGTT
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CGCAGACTCGCTGGAGAGGGATTTGGACGCGCCCTCGCCCATGCATGAAGGGGACCAAACTCGCGCGTCAG
CAAGCCCCAAGAAGAAGAGAAAGGTGGAGGCCAGCGGTACCAACCATGACCAGGAATTTGACCCCCCAAAG
GTTTACCCACCTGTGCCAGCTGAGAAGAGGAAGCCCATCCGCGTGCTGTCTCTCTTTGATGGGATTGCTAC
AGGGCTCCTGGTGCTGAAGGACCTGGGCATCCAAGTGGACCGCTACATTGCCTCCGAGGTGTGTGAGGACT
CCATCACGGTGGGCATGGTGCGGCACCAGGGAAAGATCATGTACGTCGGGGACGTCCGCAGCGTCACACAG
AAGCATATCCAGGAGTGGGGCCCATTCGACCTGGTGATTGGAGGCAGTCCCTGCAATGACCTCTCCATTGT
CAACCCTGCCCGCAAGGGACTTTATGAGGGTACTGGCCGCCTCTTCTTTGAGTTCTACCGCCTCCTGCATG
ATGCGCGGCCCAAGGAGGGAGATGATCGCCCCTTCTTCTGGCTCTTTGAGAATGTGGTGGCCATGGGCGTT
AGTGACAAGAGGGACATCTCGCGATTTCTTGAGTCTAACCCCGTGATGATTGACGCCAAAGAAGTGTCTGC
TGCACACAGGGCCCGTTACTTCTGGGGTAACCTTCCTGGCATGAACAGGCCTTTGGCATCCACTGTGAATG
ATAAGCTGGAGCTGCAAGAGTGTCTGGAGCACGGCAGAATAGCCAAGTTCAGCAAAGTGAGGACCATTACC
ACCAGGTCAAACTCTATAAAGCAGGGCAAAGACCAGCATTTCCCCGTCTTCATGAACGAGAAGGAGGACAT
CCTGTGGTGCACTGAAATGGAAAGGGTGTTTGGCTTCCCCGTCCACTACACAGACGTCTCCAACATGAGCC
GCTTGGCGAGGCAGAGACTGCTGGGCCGATCGTGGAGCGTGCCGGTCATCCGCCACCTCTTCGCTCCGCTG
AAGGAATATTTTGCTTGTGTGAGCAGCGGCAACAGCAACGCCAACAGCCGCGGCCCCAGCTTCAGCAGCGG
CCTGGTGCCCCTGAGCCTGCGCGGCAGCCACATGGGCCCTATGGAGATATACAAGACAGTGTCTGCATGGA
AGAGACAGCCAGTGCGGGTACTGAGCCTTTTTAGAAATATTGATAAAGTACTAAAGAGTTTGGGCTTTTTG
GAAAGCGGTTCTGGTTCTGGGGGAGGAACGCTGAAGTACGTGGAAGATGTCACAAATGTCGTGAGGAGAGA
CGTGGAGAAATGGGGCCCCTTTGACCTGGTGTACGGCTCGACGCAGCCCCTAGGCAGCTCTTGTGATCGCT
GTCCCGGCTGGTACATGTTCCAGTTCCACCGAATCCTGCAGTATGCGCTGCCTCGCCAGGAGAGTCAGCGG
CCCTTCTTCTGGATATTCATGGACAATCTGCTGCTGACTGAGGATGACCAAGAGACAACTACCCGCTTCCT
TCAGACAGAGGCTGTGACCCTCCAGGATGTCCGTGGCAGAGACTACCAGAATGCTATGCGGGTGTGGAGCA
ACATTCCAGGGCTGAAGAGCAAGCATGCGCCCCTGACCCCAAAGGAAGAAGAGTATCTGCAAGCCCAAGTC
AGAAGCAGGAGCAAGCTGGACGCCCCGAAAGTTGACCTCCTGGTGAAGAACTGCCTTCTCCCGCTGAGAGA
GTACTTCAAGTATTTTTCTCAAAACTCACTTCCTCTTGCTAGCGACTACAAAGACCATGACGGTGATTATA
AAGATCATGACATCGACTACAAGGATGACGATGACAAGTCTAGGGCAGTGGAGAGGGCAGAGGAAGTCTGC
TAACATGCGGTGACGTCGAGGAGAATCCTGGCCCAGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTG
CCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGA
ATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACC
CTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACTT
CTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACA
AGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTC
AAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGC
CGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGC
TCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTG
AGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGAC
CGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAA

Legend:
TALE N-Terminus and C-Terminus
p16 TALE repeat domain
Dnmt3a-3L
2A GFP
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Figure 3.8. Jumbled p16 TALE repeat domain.

CTGACCCCCGAGCAAGTCGTCGCCATCGCCAGTAACGGAGGCGGCAAACAAGCCCTGGAGACTGTCCAACG
ACTTTTGCCTGTTCTCTGCCAGGCCCATGGTTTGACTCCTGAGCAGGTGGTGGCTATAGCTTCCCATGACG
GTGGTAAACAAGCTTTGGAGACTGTTCAGAGGCTGCTGCCGGTGTTGTGTCAAGCGCACGGCCTTACGCCG
GAACAGGTCGTGGCGATTGCGTCACATGACGGGGGGAAACAAGCGCTCGAAACCGTGCAACGGCTTCTGCC
CGTCTTGTGCCAGGCTCATGGGCTCACCCCGGAGCAGGTTGTTGCTATCGCATCTAACGGAGGAGGCAAGC
AAGCGTTGGAAACGGTTCAAAGGCTTCTCCCCGTGCTCTGTCAAGCCCACGGACTTACTCCAGAGCAGGTA
GTCGCGATAGCGAGTAACGGAGGGGGTAAGCAAGCTCTCGAAACTGTACAGAGACTGCTTCCGGTACTTTG
CCAGGCACATGGCTTGACACCGGAGCAAGTTGTAGCCATTGCCTCAAACCACGGTGGGAAGCAAGCCCTTG
AGACAGTCCAGCGATTGCTGCCTGTATTGTGTCAAGCTCACGGTTTGACGCCCGAACAAGTCGTAGCTATC
GCTAGCCATGACGGCGGGAAGCAGGCTCTTGAAACAGTTCAGCGGTTGCTTCCCGTACTCTGTCAGGCTCA
CGGCCTGACTCCCGAACAGGTCGTTGCCATAGCCTCTCATGACGGCGGTAAACAGGCCTTGGAAACTGTCC
AAAGACTTCTTCCTGTCTTGTGTCAGGCCCACGGGCTTACCCCCGAGCAGGTTGTGGCCATTGCATCAAAC
ATCGGAGGTAAGCAGGCGCTGGAGACTGTGCAACGCCTTCTGCCAGTTTTGTGCCAGGCGCACGGACTTAC
ACCTGAACAGGTAGTGGCAATTGCAAGCAACATCGGAGGGAAACAGGCCCTCGAAACGGTACAGCGGCTGC
TCCCTGTGCTCTGCCAAGCCCATGGATTGACCCCAGAGCAAGTAGTTGCGATAGCCTCACATGACGGTGGA
AAGCAGGCATTGGAGACAGTGCAGCGCCTGTTGCCCGTTCTTTGCCAAGCTCATGGTCTTACACCCGAGCA
AGTGGTCGCAATCGCGTCTAACCACGGGGGCAAACAGGCTCTCGAAACCGTACAACGACTCCTTCCAGTGC
TTTGTCAAGCGCATGGCCTCACGCCAGAACAGGTGGTAGCGATCGCGAGCCATGACGGGGGGAAACAGGCA
CTTGAAACCGTTCAACGCCTCTTGCCAGTCCTGTGCCAGGCACACGGTCTGACACCAGAGCAGGTGGTTGC
AATTGCGAGTAACGGAGGAGGGAAGCAAGCACTCGAAACAGTACAGCGACTCCTCCCTGTGCTGTGCCAAG
CTCACGGATTGACCCCTGAACAAGTTGTAGCGATAGCATCTAACCACGGCGGAAAACAGGCGCTGGAAACG
GTGCAAAGGCTCCTTCCCGTTCTTTGTCAGGCCCATGGCCTCACTCCGGAACAAGTCGTCGCTATTGCTAG
TAACCACGGTGGCAAGCAGGCCCTTGAAACGGTCCAGAGGTTGTTGCCGGTCCTCTGTCAAGCACATGGGC
TCACACCAGAACAAGTAGTAGCAATAGCCAGCCATGACGGAGGAAAACAAGCACTTGAGACAGTACAAAGA
CTCCTCCCAGTACTGTGCCAAGCACACGGGCTGACGCCTGAACAAGTGGTTGCAATCGCTTCAAACGGAGG
TGGAAAGCAAGCTCTGGAAACTGTTCAGCGCTTGCTCCCGGTTCTGTGTCAGGCGCATGGA
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Table 3.1. PCR primers for amplification of bisulfite converted genomic DNA. Primers were
designed to PCR amplify regions of interest from bisulfite converted genomic DNA. Each primer
pair amplifies an approximately 250-300 base pair region within the CpG island closest to the
transcription start site of the gene analyzed. In instances where there was not a CpG island near
the gene, the promoter was evaluated. Amplicons were subsequently used to prepare DNA
sequencing libraries for DNA methylation analysis.

Locus

Coordinates

CDKN2A
_1
CDKN2A
_2
CDKN2A
_3
CDKN2A
_4
CDKN2A
_CGI2
CDKN2A
_CGI3
CDKN2A
_CGI3_2

chr9:21,975,07
5-21,975,330
chr9:21,974,90
9-21,975,178
chr9:21,974,59
7-21,974,918
chr9:21,974,55
8-21,974,863
chr9:21,970,93
0-21,971,229
chr9:21,968,28
0-21,968,569
chr9:21,968,55
1-21,968,805
chr7:5,570,3765,570,636
chr9:22,009,01
2-22,009,290
chr9:22,008,86
3-22,009,088
chr9:21,995,62
9-21,995,928
chr9:21,802,50
5-21,802,762
chr9:21,481,64
2-21,481,862
chr1:51,435,51
4-51,435,751
chr19:10,679,8
09-10,680,058
chr6:36,651,74
2-36,651,971
chr12:12,869,8
46-12,870,092
chr11:2,907,68
1-2,907,919
chr13:48,877,3
60-48,877,609
chr12:58,145,8
66-58,146,110
chr7:92,462,91
2-92,463,146
chr11:69,455,8
80-69,456,104

ACTB
CDKN2B
_1
CDKN2B
_2
p14ARF
MTAP
IFNE
CDKN2C
CDKN2D
CDKN1A
CDKN1B
CDKN1C
RB1
CDK4
CDK6
CCND1

Forward (5’ to 3’)

Reverse (5’ to 3’)

ATTTGGTAGTTAGGAAGGTTGTA

CCCTAAAATCCCCCCAAATTAAATCTC
C

GGTGGGGAGGAGTTTAGT

AACCAACCCCTCCTCTTT

GGGGTTGGTTGGTTATTAGAG

CCTAATTCCAATTCCCCTACAAACTT

AGAGGGGGAGAGTAGGTA

CCAAAAAACCTCCCCTTTTTCC

GTATGGTTATTGTTTTTGGTGTTT

ACCATTCTATTCTCTCTAACAAATCA

AGGTTAAAGATGTGTGGTATATT

ACAACCACTAAAACTCATTATATAAC

AATGAGTTTTAGTGGTTGTTTATAAT

AACACATAAATAAATAAACATCCATT

TGGGAGTTTAGTGTTTAAGAGATGTTT
A

CCCTCTCCCCTCCTTTTAC

AGGAGGGGTAGTGAGGATT

ACACTCTTCCCTTCTTTCC

GGGTAATGAAGTTGAGTTTAGG

CACCTTCTCCACTAATCCC

TGGGAATAGTAAAAGTAGGGTAAGG

ACACCCACCCACTCAAAC

GGAAAGGTTTGTAAAAGGG

AATACCAAAAACCATATCTACAC

GAAAAGGGAATTTGAAAATTTAATGT

AATAAAAACCAACAACACCAACACA

GGAGGATTTGTTTTTGTAGTTTTG

CACAAACACACATACATTCCTAATT

TTTATAGGGTTTGTATAATTAGTGG

CTACCTCCCTTCCCTCAAA

GATTAGTTGGAAGGAGTGAGAGA

ACTCAACTACTCCCTATCCACTAAAC

GGGTAGAGTTGGGGGTAG

ACAAACCTACTCTAACTAACCT

GGTTTGGTTTAAGGTTGAGAAG

AACCCTCACACACCTACT

GTGATTTTAAAAGGTTAGTAAGTG

AAACCTCATCCCTATCCC

GGTGAGGGGGTTTTTTTAGT

ACCCTTCCATAACCAACTC

GGTTTGGGAGAGGGTAGG

ATCCCTCCTCTTCCCTCC

ATTATAGGGGAGTTTTGTTGAAGTT

CAACACAAAAACTAATATTCCATAAC
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Table 3.2. qPCR primers for gene expression analysis
Locus

Forward (5’ to 3’)

Reverse (5’ to 3’)

HPRT1

GCAGACTTTGCTTTCCTTGG

AACACTTCGTGGGGTCCTTT

CDKN2A
(p16)

CCCAACGCACCGAATAGTT

AGCAGCAGCTCCGCCACT

CDKN2A
(p14ARF)

AGAACATGGTGCGCAGGT

GGGATGTGAACCACGAAAAC

CDKN2B

GCTGTTTCATCAGCAGCCTA

CCACAATGGAGCTAGAAGCA

MTAP

CTACCTCAGGGCATGGTTGT

TGCTGGCTAAATGCTTGTTG

IFNE

ACCCTTGAACGACATGAAGC

AAGAATCATGTCTGGAGAAGTCC

CDKN2C

GTGATTTGGCCAGGCTCTAT

AGCCCTCCCCACGTTTATT

CDKN2D

CCAAGGGCAGAGCATTTAAG

AAGCAACGTGCACACTTCAG

CDKN1A

GATTAGCAGCGGAACAAGGA

CAACTACTCCCAGCCCCATA

CDKN1B

GAGGTGCTTGGGAGTTTTGA

TGTTTACACAGCCCGAAGTG

CDKN1C

CAGCGTTCGGTTTTGTTTTT

GGGACCAGTGTACCTTCTCG

RB1

AGGGCTTACTATTTCTGGGTCTT

CAATACACGATCTCTGAAGTTCC

CDK4

CGAGCTCTGCAGCACTCTTA

AGAAGGGAAATGGCAGCTTT

CDK6

TGTCTATCTCCCGGCACTTC

TGAAAGCAAGCAAACAGGTG

CCND1

AGCGCTGTTTTTGTTGTGTG

CTTGCCTCAAAGTCCTGCTT

79	
  
	
  

CHAPTER 4 – The BisPCR2 method for targeted bisulfite sequencing
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2
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Abstract
DNA methylation has emerged as an important regulator of development and disease,
necessitating the design of more efficient and cost-effective methods for detecting and quantifying
this epigenetic modification. Next-generation sequencing (NGS) techniques offer single base
resolution of CpG methylation levels with high statistical significance, but are also high cost if
performed genome-wide. Here, we describe a simplified targeted bisulfite sequencing approach
in which DNA sequencing libraries are prepared following sodium bisulfite conversion and two
2

rounds of PCR for target enrichment and sample barcoding, termed BisPCR . We have applied
2

the BisPCR technique to validate differential methylation at several type 2 diabetes risk loci
identified in genome-wide studies of human islets. We confirmed some previous findings while
not others, in addition to identifying novel differentially methylated CpGs at these genes of
2

interest, due to the much higher depth of sequencing coverage in BisPCR compared to prior
array-based approaches. This study presents a robust, efficient, and cost-effective technique for
targeted bisulfite NGS, and illustrates its utility by reanalysis of prior findings from genome-wide
studies.
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Introduction
DNA methylation refers to the addition of a methyl group to the 5-carbon position of
cytosine residues, and in mammalian genomes occurs most commonly in the context of CpG
dinucleotides.

As an epigenetic mark, this chemical modification does not alter the DNA

sequence, but rather regulates transcriptional programs to direct processes such as cellular
differentiation, genomic imprinting, and X-chromosome inactivation, while promoting genomic
stability (Callinan and Feinberg 2006; Reik et al. 2001; Calvanese et al. 2009; Sheaffer et al.
2014). The majority of CpGs throughout the mammalian genome are fully methylated, while the
remainder exists in an unmethylated or lowly methylated state, corresponding to active regulatory
elements such as promoters and enhancers (Lister et al. 2009; Stadler et al. 2011; Ziller et al.
2013; Baubec and Schuebeler 2014; Sheaffer et al. 2014). Aberrant DNA methylation has been
implicated in an increasing number of morbidities, particularly cancer and aging-associated
diseases such as type 2 diabetes, neurological disorders, and cardiovascular disease (Bergman
and Cedar 2013; Heerboth et al. 2014; Hamm and Costa 2015). Many of the studies linking DNA
methylation to disease have been prompted by the observation that only a small fraction of the
inherited risk of these complex disorders can be explained by genetic variation, as determined by
genome-wide association studies (GWAS) (Petronis 2010; Rakyan et al. 2011).

DNA

methylation, along with other epigenetic alterations, may provide the link between environmental
factors or intrauterine exposure and complex disorders.
A key challenge in the epigenetics field has been achieving high-resolution genome-wide
detection of these modifications in sufficient sample sizes to make claims about disease
association. In mapping DNA methylation, the most advanced technologies include array-based
techniques such as the Infinium HumanMethylation450 BeadChip, which assays 450,000
individual CpGs among 99% of RefSeq genes, and whole genome shotgun bisulfite sequencing
(WGBS), which maps cytosine methylation across the entire genome at single base resolution,
covering approximately 30 million CpGs. While array-based approaches are more cost-effective
and higher throughput, the restrictive sampling of CpGs provides an incomplete landscape of the
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methylome (Lee et al. 2013). However, WGBS experiments are extremely resource-intensive,
because exhaustive sequencing is required to achieve sufficient coverage to accurately
determine the percentage of methylation at all CpGs. Therefore, it is only practical to conduct
WGBS on a limited number of samples, and coverage is usually in the range of 5-15X per CpG,
limiting statistical significance of findings. In both instances, novel findings need to be validated
in larger populations through targeted methylation analyses. Thus, there is an increasing need
for targeted sequencing techniques that are high throughput, cost effective, and provide single
base resolution.
Next generation sequencing (NGS) strategies have been developed as an alternative to
fluorescence-based pyrosequencing, which is limited by the number of samples that can be
processed, and the fact that its short read lengths cover only a few CpGs at a time. These
protocols entail PCR amplification of target regions from bisulfite-converted genomic DNA,
followed by DNA sequencing library preparation using techniques such as standard Illumina
protocols or transposase-based Nextera XT technology (Morrill et al. 2013; Masser et al. 2013).
While providing precise and accurate DNA methylation data with high statistical significance, DNA
sequencing library preparation is quite expensive and cumbersome when evaluating large
numbers of samples or target regions.
Therefore, we have developed a novel approach for constructing targeted bisulfite NGS
libraries that are prepared by bisulfite conversion of genomic DNA followed by two rounds of
2

PCR, termed BisPCR , eliminating the need for traditional DNA library preparation procedures
2

(Figure 4.1). In the BisPCR method, the entire library preparation process has been reduced to
a single 50-minute PCR reaction. We have validated the usefulness of this method in the context
of type 2 diabetes, first confirming reported differences in DNA methylation at the imprinted
MEG3 locus, and by validation of previous genome-wide findings of CpG risk loci identified in
type 2 diabetic human islets (Kameswaran et al. 2014; Dayeh et al. 2014).
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Results
2

The BisPCR method for targeted bisulfite sequencing
In order to simplify targeted bisulfite NGS, we developed a PCR-based method for library
2

preparation, termed BisPCR (Figure 4.1). The first step in this procedure is sodium bisulfite
treatment of genomic DNA (gDNA), which deaminates unmethylated cytosines to uracils, while
methylated cytosines are protected.

In subsequent PCR amplification reactions, uracils are

amplified and ultimately sequenced as thymine residues. The goal of the first PCR (PCR#1) is
target enrichment to amplify regions of interest from bisulfite converted gDNA.

The target

enrichment primers have overhangs with partial adapter sequences that are subsequently used to
amplify barcoded libraries in the second round of PCR (PCR#2).

Target enrichment PCR

products (PCR#1) for each sample are pooled prior to PCR#2 to simultaneously add the same
multiplexing indeces to all amplicons of interest.

Following sample barcoding, all PCR#2

reactions are purified and pooled for sequencing on the Illumina Miseq with 150 base pair pairedend reads. We found that purification of final libraries with AMPure XP beads efficiently removed
primer dimers in comparison to column based PCR purification (data not shown). To prove that
2

BisPCR is comparable to traditional targeted bisulfite NGS approaches, we measured DNA
methylation at the H19 locus in mouse genomic DNA using both methods and found nearly
identical results (Figure 4.2).

2

BisPCR library construction and sequencing
In this study, we selected five target loci for evaluation, as described below, and
compared their DNA methylation profile in five non-diabetic and five type 2 diabetic human islet
samples. Donor information is provided in Table 4.1. Thus, for each of these ten biological
samples, five PCR#1 amplicons were pooled, purified, and then used as template for the PCR#2
barcoding reaction. Target regions ranged in size from 171 to 298 bps (Table 4.2), and PCR#2
conditions were optimized to prevent amplification bias, particularly of smaller fragments, with the
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goal of balancing each library with roughly equivalent amounts of each amplicon (Figures 4.3A
and 4.3B).
The MiSeq sequencing run produced 14.15 million reads, with 12.75 million passing filter.
The sample was spiked with 10% PhiX control, and 8.5% of total reads were aligned to the PhiX
genome.

Approximately 85% of remaining reads, or 10 million, were aligned to the human

genome. Therefore, the expected number of reads per amplicon per sample was approximately
200,000 reads. The percentage of reads allocated to each of the ten samples ranged from 7.01%
to 12.45% (Figure 4.3C). The slight deviation from the expected 10% per sample is likely due to
small pipetting errors when preparing the sequencing pool. Across all samples, the average read
number per locus was 206,411, ranging from 78,000 to 358,000 reads (Figure 4.3C). The range
in sequencing depth is likely due to imprecise pooling of PCR#1 products. The amount of each
PCR#1 product pooled was based on relative band intensity of one representative sample, nondiabetic 1 (ND1), run on a 1.5% agarose gel, and does not account for sample to sample
variability, which we anticipated to be low. This approximation is suitable for many applications of
2

the BisPCR method, although samples could be assessed for pooling independently if so
desired. Nevertheless, even the minimal read depth of 78,000 allows for exceedingly precise
determination of methylation levels.

Validation of type 2 diabetes differentially methylated loci
2

We tested our BisPCR targeted bisulfite sequencing approach by measuring DNA
methylation of the promoter region of MEG3 in human pancreatic islets. MEG3 is a complex
imprinted locus that produces 54 microRNAs, the MEG3 lncRNA, and multiple additional small
RNA species.

MEG3 was shown to be down-regulated with corresponding promoter

hypermethylation in type 2 diabetic (T2D) human islets (Kameswaran et al. 2014). As an
imprinted locus, the MEG3 promoter is expected to be approximately 50% methylated in normal
2

human islets, and thus it is an ideal target for validating the BisPCR strategy.
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Target enrichment primers were designed to amplify a 298 base pair region within the
MEG3 promoter at position -188 to -493 relative to the transcription start site. This amplicon
covered 19 CpGs, and the average CpG methylation across the region was significantly
increased from 43% in non-diabetic to 61% in type 2 diabetic human islets (p < 0.0001),
confirming the report by Kameswaran and colleagues.

Of the 19 CpGs covered, 14 had

significantly increased CpG methylation in type 2 diabetics (p < 0.05) (Figure 4.4A). To further
corroborate our findings, using primers directed to the same target region, we technically
validated our results with pyrosequencing. Although the same target region was analyzed, the
fluorescence-based pyrosequencing reaction covered only 2 of the 19 CpGs within the amplicon,
#15 and #16. These 2 CpGs showed comparable levels of CpG methylation in the non-diabetic
2

and type 2 diabetic samples as the BisPCR method (Figure 4.4B). Thus, we were able to
technically validate our results with pyrosequencing, and analyze ten times as many CpGs with
2

the BisPCR method.
2

We next sought to employ the BisPCR strategy to validate published differentially
methylated loci in islets from type 2 diabetics (Dayeh et al. 2014). We selected four genes, INS,
IRS1, CDKN1A, and PDE7B, for validation. These loci were among those determined by Dayeh
and colleagues to be differentially methylated in type 2 diabetic human islets in a genome-wide
screen conducted with the Infinium HumanMethylation450 BeadChip array (Dayeh et al. 2014).
The insulin gene has also been described as differentially methylated in type 2 diabetic human
islets through a candidate gene approach (Yang et al. 2011). We designed PCR#1 primers
targeting the region -112 to -336 base pairs upstream of the insulin transcription start site
capturing four CpGs, three of which were previously reported to have increased DNA methylation
in type 2 diabetic human islets (Dayeh et al. 2014). We found all four CpGs measured had
significantly increased DNA methylation (p < 0.05) with an average of 24% in non-diabetic
compared to 46% in type 2 diabetic samples (p < 0.0005) (Figure 4.5A). This includes one CpG
from the Infinium array that was not previously identified as differentially methylated, INS CpG #4
(cg24338752).
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Individual CpGs within the other three loci had previously been re-analysed by
pyrosequencing, and we modified these pyrosequencing primers with PCR#1 adapter overhangs
2

to adapt these amplicons to the BisPCR technology (Dayeh et al. 2014). By using the BisPCR

2

method with the same amplicons we were able to directly quantify DNA methylation at all CpGs
within the target region. At the IRS1 locus, we measured a comparable decrease of 10% CpG
methylation in type 2 diabetic human islets, from 47% to 37%, at IRS1 CpG #1 (cg04751089), as
had been reported previously (Figure 4.5B) (Dayeh et al. 2014).

In this amplicon we also

determined DNA methylation at two adjacent CpGs that were not included in the Infinium array,
and while the changes trended in a similar direction, there was no significant difference between
non-diabetic and type 2 diabetic samples. At the CDKN1A locus, we did not find a significant
difference in DNA methylation at the CpG previously analysed by pyrosequencing, CDKN1A CpG
#1 (cg21091547), but did observe a significant decrease of 10% at two adjacent CpGs captured
in this amplicon (Figure 4.5C).

CDKN1A CpG #3 (cg24425727) was also identified as

differentially methylated to a similar extent in the genome-wide study by Dayeh and colleagues,
while CDKN1A CpG #2 (cg11920449) was not previously identified as differentially methylated
(Dayeh et al. 2014). Lastly, we did not observe a change in DNA methylation at any of the three
2

CpGs assayed at the PDE7B locus (Figure 4.5D). Thus, in our validation study using BisPCR ,
we were able to confirm some previous genome-wide findings and not others, while making novel
observations about additional nearby CpGs not covered in prior assays.
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Discussion
2

We were prompted to develop the BisPCR method by our need for a high-throughput,
cost-effective method for interrogating multiple CpGs at base resolution within multiple target loci
of interest. Fluorescence-based approaches to targeted bisulfite sequencing are limited by the
number of CpGs that can be measured at one time, the inability to multiplex, and the reliance of
measurements on a secondary enzymatic reaction. Next generation sequencing techniques for
targeted bisulfite sequencing employ the same strategy of bisulfite conversion and amplification
of target loci, but result in a far more robust output by directly measuring base content of each
CpG within an amplicon. Further, the ability to multiplex means that a single sequencing reaction
can yield information about multiple target loci for multiple biological samples. One impediment of
NGS approaches is the additional step of DNA sequencing library preparation following target
enrichment, which can be expensive and time consuming. We have circumvented this challenge
by modifying the target enrichment PCR primers with overhangs such that DNA sequencing
libraries can be directly amplified from target enrichment amplicons.

This modification

dramatically decreases time and expense required for this NGS approach.
2

We technically validated the BisPCR method at the imprinted MEG3 locus, which was
previously shown to be hypermethylated in type 2 diabetic human islets (Kameswaran et al.
2

2014). We confirmed previous findings by both BisPCR and pyrosequencing and demonstrated
2

that BisPCR measures DNA methylation at 19 CpGs, while pyrosequencing measures only two
despite identical target sequence inputs. Further, our validation study of type 2 diabetes CpG risk
loci highlights several important considerations about implementing targeted DNA methylation
analysis, particularly as a diagnostic marker. In some instances, such as IRS1, our results were
nearly identical to those reported by Dayeh and colleagues (Dayeh et al. 2014). We found similar
levels of DNA methylation in normal and type 2 diabetic human islets at IRS CpG #1
(cg04751089) and found no significant changes at two adjacent CpGs that were not probed for on
the Infinium HumanMethylation450 BeadChip. However, in contrast to genome-wide findings, we
did not observe a change in DNA methylation at PDE7B CpG #2 (cg27306443), or at adjacent
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CpGs. While this discrepancy may be due to our limited sample size, it stresses the point that
CpG methylation at this locus is not a sufficient diagnostic indicator of type 2 diabetes. Our
findings at the CDKN1A locus highlight a third point, as we did not measure a change in CpG
methylation at the reported cg21091547 (CDKN1A CpG #1), but did find a significant decrease in
methylation at two adjacent CpGs, one of which was also identified by Dayeh and colleagues
(Dayeh et al. 2014). These results again stress the danger of relying on a single CpG for
reporting methylation changes, and also emphasize the value in incorporating multiple CpGs for
the understanding of how DNA methylation is implicated in disease risk.
2

While we have demonstrated the utility of BisPCR in validating findings from genomewide DNA methylation analyses, this technology is also suitable for other applications including
candidate gene approaches and clinical diagnostic assays.

In candidate gene approaches,

where genome-wide analyses may not be possible, many regions can be surveyed
simultaneously by pooling multiple PCR#1 products across larger sample sizes than would be
feasible for fluorescence-based assays. Clinical applications can benefit as well by reducing the
costs of NGS approaches while collecting high-resolution data about neighbouring CpGs, the
value of which was discussed earlier. It should also be noted that our particular study does not
take full advantage of the sequencing capacity of the MiSeq, as 200,000 reads per amplicon is
orders of magnitude beyond what would be sufficient to draw statistically significant conclusions.
Considering a sequencing threshold of 1,000 reads per amplicon, the capacity of the number of
amplicons and samples that can be analysed in one run could be increased by two hundred-fold.
This excess capacity could be distributed to additional samples or additional target loci, or a
combination of both.

We provide 48 single index barcoding primers based on widely used

Illumina sequencing technology, which would accommodate 250 target loci per sample. Further,
the barcoding primers could easily be modified with dual indeces to increase multiplexing
capacity, which may be of particular utility in a clinical assay.
BisPCR

2

is an efficient, cost-effective, and robust high-throughput technique for

assessing DNA methylation at targeted loci of interest.
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Replacing DNA sequencing library

preparation with a single round of PCR represents a significant improvement over other targeted
bisulfite NGS approaches by reducing time and cost. This method is easily adaptable to different
experimental setups to address a wide variety of biological questions relevant to DNA
methylation.
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Methods
Traditional targeted bisulfite NGS library preparation (BisPCRSeq)
100 ng of mouse genomic DNA, isolated from the intestinal epithelium of three month old
C57BL/6J-ApcMin/J mice (Jackson Laboratories), was bisulfite converted using the Epitect
bisulfite kit (Qiagen).

Template DNA was amplified using KAPA HIFI Uracel+ (KAPA) with

primers directed to the H19 locus (Forward: 5’ – ATTAGTTAGTGTGGTTTATTATAGGAAG – 3’
and Reverse: 5’ – AACCATTCCAAAAATACACACATCTTA – 3’).

Sequencing libraries were

made using the NEBNext Multiplex Sample Kit (NEB). These primers were also modified for
2

incorporation into the BisPCR library preparation protocol, as described below.

Genomic DNA isolation and sodium bisulfite conversion
Primary human islets were obtained from the Integrated Islet Distribution Program (IIDP).
10,000 islet equivalents were obtained from five non-diabetic and five type 2 diabetic donors.
Genomic DNA (gDNA) was extracted using the Qiagen® AllPrep DNA/RNA mini kit (Cat. No.
80204) following the manufacturer’s instructions.

500ng of gDNA was treated with sodium

bisulfite to convert unmethylated cytosines using the Qiagen® EpiTect® Bisulfite Kit (Cat. No.
59104). Reactions were carried out per the manufacturer’s protocol.

Target Enrichment (PCR#1)
Bisulfite converted gDNA was PCR amplified to enrich for regions of interest for DNA
methylation analysis. Primers directed to target regions were modified with the following partial
adapter

overhangs:

PCR#1

Left

Primer

Overhang:

5’

–

ACACTCTTTCCCTACACGACGCTCTTCCGATCT – 3’; PCR#1 Right Primer Overhang: 5’ –
GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT – 3’. Primers directed to the MEG3 and
INS loci were designed using the Qiagen® PyroMark assay Design software.

Primers for

CDKN1A, PED7B and IRS1 were adapted from a recent study by Dayeh and colleagues (Dayeh
et al. 2014). Primer sequences and genomic coordinates are provided in Table 4.3.
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PCR

reactions were prepared with the Qiagen® PyroMark PCR Kit (Cat. No. 978703) per the
manufacturer’s recommendations using 2.8ng of bisulfite converted gDNA template per reaction
and the suggested optimized cycling protocol.

All PCR#1 products for individual biological

samples were pooled based on relative band intensity when 5µl of PCR#1 reaction from a
representative sample, non-diabetic 1, was analysed on a 1.5% agarose gel. Final amounts were
combined as follows: MEG3: 6µl, CDKN1A: 8µl, PED7B: 4µl, IRS1: 4µl, INS: 4µl, for a total of
26µl per biological sample. Each pool of PCR products was purified with the Qiagen® QIAquick
PCR Purification Kit (Cat. No. 28104) per the manufacturer’s instructions. A detailed diagram of
2

BisPCR primer design is provided in Figure 4.6.

Sample barcoding (PCR#2)
Unique DNA sequencing barcodes were incorporated into each sample by a subsequent
round of PCR amplification.

Barcoding primers are provided in Table 4.4.

The Qiagen®

PyroMark PCR kit was used to amplify 1ng of pooled PCR#1 template. Thermocycling conditions
were modified to ensure consistent amplification of PCR products of different sizes and were as
follows: 95°C – 15 min; 10 cycles: 94°C – 30 sec, touchdown 68°C to 56°C – 30 sec, 72°C – 1
min; 72°C – 10 min.

PCR products were purified with Agencourt® AMPure® XP beads

(Beckman Coulter, Cat. No. A63881). Sample concentrations were measured using the Qubit®
fluorometer (Life Technologies) dsDNA high sensitivity assay. Fragment length was determined
by separating 1ng of sample on an Agilent high sensitivity DNA assay using the 2100 Bioanalyzer
(Agilent Technologies). The molarity of the libraries was quantified using the KAPA library
quantification assay (Kapa Biosystems, Cat. No. KK4873).

Next-Generation Sequencing
Next generation sequencing was carried out on the Illumina MiSeq using Reagent Kit v2
2

following the manufacturer’s instructions. Briefly, a 2nM pool of BisPCR libraries and 2 nM PhiX
control were each denatured for five minutes with 0.2N NaOH and diluted to final concentrations
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of 6pM and 8pM, respectively. The denatured pool was spiked with 10% denatured PhiX control
and 600µl of the prepared sample was loaded into the reagent cartridge.

The sequencing

reaction was carried out with 150 base pair paired-end sequencing. Sequences were aligned to
an in silico bisulfite-converted human genome using the BS Seeker program, and any CpGs
covered by the first sequencing read were ignored in the second sequencing read in paired-end
sequencing (Chen et al. 2010). The fraction of methylated cytosines was calculated as the
merged frequency of cytosines for CpGs divided by total reads.

Sequencing and DNA

methylation analysis were carried out by the Next Generation Sequencing Core at the University
of Pennsylvania (Philadelphia, PA) [GEO: GSE69595].

Pyrosequencing
Pyrosequencing was performed to technically validate BisPCR

2

at the MEG3

locus. Forward and reverse primers designed with Qiagen® PyroMark Assay Design software
were

used

biotinylated.

for

both

methods,

Pyrosequencing

and

for

pyrosequencing

primer

sequences

GGGGTGATAGTTTTTGGTTTATATT-3’,

Reverse:

were

the
as

reverse
follows:

primer
Forward:

was
5’-

5’-CCATAACCAACACCCTATAAT-3’,

Sequencing: 5’-TTTTTATATATTGTGTTTGAATTTA-3’. Bisulfite-converted genomic DNA from
human islets, processed as described above, was amplified with the Qiagen® PyroMark PCR Kit
(Cat. No. 978703) per the manufacturer’s protocol. The pyrosequencing reaction was carried out
using Qiagen® PyroMark Gold Q96 CDT Reagents on the PyroMark Q96 MD (QIAGEN)
according to the manufacturer’s instructions.

Statistics
Data are shown as average ± SEM (n = 5). Average percent CpG methylation was
compared by two-tailed t-tests, and significance was defined as p < 0.05.

ABBREVIATIONS
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NGS: Next generation sequencing; GWAS: genome-wide association study; WGBS: whole
genome bisulfite sequencing; PCR: polymerase chain reaction; gDNA: genomic DNA; ND: Nondiabetic; T2D: Type 2 diabetic; SEM: standard error of the mean.
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2

Figure 4.1. Schema of BisPCR method for targeted bisulfite sequencing. DNA sequencing
libraries are prepared by bisulfite conversion of genomic DNA followed by two rounds of PCR for
target enrichment (PCR#1) and subsequent sample barcoding (PCR#2).

Partial adapter

overhangs are added to target enrichment primers to permit simplified library preparation by PCR.
PCR#1 amplicons are pooled prior to the PCR#2 reaction for each biological sample. Due to the
presence of the unique barcodes, all PCR#2 amplicons can be pooled for a single nextgeneration sequencing run.
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Figure 4.2. Comparison of BisPCR and traditional targeted bisulfite NGS methods. DNA
2

methylation was measured in murine genomic DNA at the H19 locus using both BisPCR and
traditional targeted bisulfite NGS (n=3).

Traditional targeted bisulfite NGS is denoted as

BisPCRSeq.
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Figure 4.3.

2

BisPCR DNA sequencing libraries. (A) Bioanalyzer gel visualizing the five

amplicon fragments of a representative sample, ND1, following PCR#2. (B) Bioanalyzer
electropherogram quantifying the amount of each fragment in ND1, illustrating the roughly
equivalent amounts of all five amplicons. (C) Average reads per amplicon for each sample. ND,
non-diabetic; T2D, type 2 diabetic.
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Figure 4.4. BisPCR DNA methylation analysis confirms increased CpG methylation in type
2 diabetic human islets at the MEG3 locus. (A) Average percent CpG methylation at the
MEG3 locus for five non-diabetic and five type 2 diabetic human islet samples measured by
2

BisPCR . p-values calculated by a two-tailed t-test. *p < 0.05. Error bars indicate SEM. (B)
Quantification of average percent CpG methylation by pyrosequencing using the same samples
and same MEG3 PCR primer sequences as in (A). Only 2 of 19 CpGs are covered in the
pyrosequencing assay. Data displayed as in (A).
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Figure 4.5. Validation of CpG loci differentially methylated in type 2 diabetic pancreatic
2

islets by BisPCR . Average percent CpG methylation in 5 non-diabetic and 5 type 2 diabetic
human islet samples at loci previously shown to be differentially methylated in type 2 diabetic
human islets, including (A) INS, (B) IRS1, (C) CDKN1A, and (D) PDE7B. Black arrows indicate
CpGs analysed previously by pyrosequencing by Dayeh and colleagues (Dayeh et al. 2014). pvalue calculated by two-tailed t-tests. *p < 0.05. Error bars indicate SEM.
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Index-specific Adaptor!

Target!

R2!

Purple and blue text indicates primer

for each sample, shown in red. We have modified 48 different “R2,” or barcoding, primers.

and “R2” forward and reverse primers, introduce the remainder of the adapter sequence as well as a unique index

in PCR#1. Target region is indicated by the series of “N’s” between adapters. PCR#2 primers, indicated by “F2”

overhangs that are added to locus-specific forward and reverse primers, respectively, to amplify regions of interest

of adapter sequences that are introduced during PCR#1 and PCR#2.

Figure 4.6. Diagram illustrating the design of BisPCR2 primer sequences. This diagram illustrates the details

5’-GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT-3’!

Reverse Primer Overhang:!

5’-ACACTCTTTCCCTACACGACGCTCTTCCGATCT-3’!

Target Enrichment Primer Overhangs:!
Forward Primer Overhang:!

3’-TGTGCAGACTTGAGGTCAGTGTAGTGCTAGAGCATACGGCAGAAGACGAAC-5’!

R1!

Index!

NNNNNNN!
3’-NNNNNNNTCTAGCCTTCTCGTGTGCAGACTTGAGGTCAGTG-5’!

NNNNNNN!

F1! 5’-ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNNNN-3’!

5’-AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGAC-3’!

F2!

Primer sequences:!

TTACTATGCCGCTGGTGGCTCTAGATGTGAGAAAGGGATGTGCTGCGAGAAGGCTAGANNNNNNNTCTAGCCTTCTCGTGTGCAGACTTGAGGTCAGTGTAGTGCTAGAGCATACGGCAGAAGACGAAC!

AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNNNNAGATCGGAAGAGCACACGTCTGAACTCCAGTCACATCACGATCTCGTATGCCGTCTTCTGCTTG!

Universal Adaptor!

DNA Sequencing Library:!

Table 4.1. Human pancreatic islet donor information
2

Donor

Gender

Age (yrs)

BMI (kg/m )

Non-diabetic 1

M

50

29.1

Non-diabetic 2

F

59

28.3

Non-diabetic 3

M

49

31.3

Non-diabetic 4

M

60

22.5

Non-diabetic 5

M

51

38.9

Type 2 diabetic 1

M

58

29.3

Type 2 diabetic 2

M

43

37

Type 2 diabetic 3

F

40

33.9

Type 2 diabetic 4

F

57

48.4

Type 2 diabetic 5

M

47

NA
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Table 4.2. Description of PCR products assessed for DNA methylation analysis.
Locus

Coordinates

Region length (bp)

Final amplicon (bp)

MEG3

chr14: 101,291,952101,292,257

298

420

INS

chr11: 2,182,5512,182,775

225

347

IRS1

chr2: 227,659,611227,659,781

171

293

CDKN1A

chr6: 36,645,46236,645,696

235

357

PDE7B

chr6: 136,172,765136,172,917

153

275
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Table 4.3. PCR#1 primer sequences for amplification of bisulfite converted genomic DNA.
Forward and reverse target enrichment primers were modified with adapter overhangs. Locusspecific portion of primer sequences are in bold text and common adapter overhangs are in plain
text.

Primer

Sequence (5’ to 3’)

Coordinates

MEG3_F

ACACTCTTTCCCTACACGACGCTCTTCCGATCTGGGGTGATAGT
TTTTGGTTTATATT

chr14:

MEG3_R

GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTCCATAACCA
ACACCCTATAAT

CDKN1A_F

ACACTCTTTCCCTACACGACGCTCTTCCGATCTGGAGTTATAGA
AATAAAGGATGATAAGTAG

CDKN1A_R

GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTTCCCTATAAT
TACAACAACTTTATTAACCA

PDE7B_F

ACACTCTTTCCCTACACGACGCTCTTCCGATCTTGTTTTTTTTTG
TTTGTGGTAATTGATAG

PDE7B_R

GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTTCCCTAAATA
AATAACACCACTTTTCTC

IRS1_F

ACACTCTTTCCCTACACGACGCTCTTCCGATCTGGAAAGAATA
GGAAGGGGTAG

IRS1_R

GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTATTTAAACCC
CTATACCAACATCAATTTCC

INS_F

ACACTCTTTCCCTACACGACGCTCTTCCGATCTTGGGGGTTGA
GGTTGTAATT

INS_R

GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTACCTCCAAC
TCTCCTAATCTAATAT
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101,291,952101,292,257

chr6:
36,645,46236,645,696

chr6:
136,172,765136,172,917

chr2:
227,659,611227,659,781

chr11:
2,182,5512,182,775

Table 4.4. PCR#2 primer sequences for library amplification and barcoding. Amplification
with PCR#2 primers adds the remainder of adapter sequence and unique barcodes for up to 48
samples. A common forward primer, “Library_Primer1,” is used in combination with each unique
barcoding reverse primer.
Primer Name

Primer Sequence

Barcode

Library_Prim
er1
Primer2_Index
_1
Primer2_Index
_2
Primer2_Index
_3
Primer2_Index
_4
Primer2_Index
_5
Primer2_Index
_6
Primer2_Index
_7
Primer2_Index
_8
Primer2_Index
_9
Primer2_Index
_10
Primer2_Index
_11
Primer2_Index
_12
Primer2_Index
_13
Primer2_Index
_14
Primer2_Index
_15
Primer2_Index
_16
Primer2_Index
_17
Primer2_Index
_18
Primer2_Index
_19
Primer2_Index
_20
Primer2_Index
_21
Primer2_Index
_22
Primer2_Index
_23
Primer2_Index
_24
Primer2_Index
_25
Primer2_Index

AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGAC
CAAGCAGAAGACGGCATACGAGATCGTGATGTGACTGGAGTTCAGACGTGT

ALL
libraries
ATCACG

CAAGCAGAAGACGGCATACGAGATACATCGGTGACTGGAGTTCAGACGTGT

CGATGT

CAAGCAGAAGACGGCATACGAGATGCCTAAGTGACTGGAGTTCAGACGTGT

TTAGGC

CAAGCAGAAGACGGCATACGAGATTGGTCAGTGACTGGAGTTCAGACGTGT

TGACCA

CAAGCAGAAGACGGCATACGAGATCACTGTGTGACTGGAGTTCAGACGTGT

ACAGTG

CAAGCAGAAGACGGCATACGAGATATTGGCGTGACTGGAGTTCAGACGTGT

GCCAAT

CAAGCAGAAGACGGCATACGAGATGATCTGGTGACTGGAGTTCAGACGTGT

CAGATC

CAAGCAGAAGACGGCATACGAGATTCAAGTGTGACTGGAGTTCAGACGTGT

ACTTGA

CAAGCAGAAGACGGCATACGAGATCTGATCGTGACTGGAGTTCAGACGTGT

GATCAG

CAAGCAGAAGACGGCATACGAGATAAGCTAGTGACTGGAGTTCAGACGTGT

TAGCTT

CAAGCAGAAGACGGCATACGAGATGTAGCCGTGACTGGAGTTCAGACGTGT

GGCTAC

CAAGCAGAAGACGGCATACGAGATTACAAGGTGACTGGAGTTCAGACGTGT

CTTGTA

CAAGCAGAAGACGGCATACGAGATTTGACTGTGACTGGAGTTCAGACGTGT

AGTCAA

CAAGCAGAAGACGGCATACGAGATGGAACTGTGACTGGAGTTCAGACGTGT

AGTTCC

CAAGCAGAAGACGGCATACGAGATTGACATGTGACTGGAGTTCAGACGTGT

ATGTCA

CAAGCAGAAGACGGCATACGAGATGGACGGGTGACTGGAGTTCAGACGTGT

CCGTCC

CAAGCAGAAGACGGCATACGAGATCTCTACGTGACTGGAGTTCAGACGTGT

GTAGAG

CAAGCAGAAGACGGCATACGAGATGCGGACGTGACTGGAGTTCAGACGTGT

GTCCGC

CAAGCAGAAGACGGCATACGAGATTTTCACGTGACTGGAGTTCAGACGTGT

GTGAAA

CAAGCAGAAGACGGCATACGAGATGGCCACGTGACTGGAGTTCAGACGTGT

GTGGCC

CAAGCAGAAGACGGCATACGAGATCGAAACGTGACTGGAGTTCAGACGTGT

GTTTCG

CAAGCAGAAGACGGCATACGAGATCGTACGGTGACTGGAGTTCAGACGTGT

CGTACG

CAAGCAGAAGACGGCATACGAGATCCACTCGTGACTGGAGTTCAGACGTGT

GAGTGG

CAAGCAGAAGACGGCATACGAGATGCTACCGTGACTGGAGTTCAGACGTGT

GGTAGC

CAAGCAGAAGACGGCATACGAGATATCAGTGTGACTGGAGTTCAGACGTGT

ACTGAT

CAAGCAGAAGACGGCATACGAGATGCTCATGTGACTGGAGTTCAGACGTGT

ATGAGC
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_26
Primer2_Index
_27
Primer2_Index
_28
Primer2_Index
_29
Primer2_Index
_30
Primer2_Index
_31
Primer2_Index
_32
Primer2_Index
_33
Primer2_Index
_34
Primer2_Index
_35
Primer2_Index
_36
Primer2_Index
_37
Primer2_Index
_38
Primer2_Index
_39
Primer2_Index
_40
Primer2_Index
_41
Primer2_Index
_42
Primer2_Index
_43
Primer2_Index
_44
Primer2_Index
_45
Primer2_Index
_46
Primer2_Index
_47
Primer2_Index
_48

CAAGCAGAAGACGGCATACGAGATAGGAATGTGACTGGAGTTCAGACGTGT

ATTCCT

CAAGCAGAAGACGGCATACGAGATCTTTTGGTGACTGGAGTTCAGACGTGT

CAAAAG

CAAGCAGAAGACGGCATACGAGATTAGTTGGTGACTGGAGTTCAGACGTGT

CAACTA

CAAGCAGAAGACGGCATACGAGATCCGGTGGTGACTGGAGTTCAGACGTGT

CACCGG

CAAGCAGAAGACGGCATACGAGATATCGTGGTGACTGGAGTTCAGACGTGT

CACGAT

CAAGCAGAAGACGGCATACGAGATTGAGTGGTGACTGGAGTTCAGACGTGT

CACTCA

CAAGCAGAAGACGGCATACGAGATCGCCTGGTGACTGGAGTTCAGACGTGT

CAGGCG

CAAGCAGAAGACGGCATACGAGATGCCATGGTGACTGGAGTTCAGACGTGT

CATGGC

CAAGCAGAAGACGGCATACGAGATAAAATGGTGACTGGAGTTCAGACGTGT

CATTTT

CAAGCAGAAGACGGCATACGAGATTGTTGGGTGACTGGAGTTCAGACGTGT

CCAACA

CAAGCAGAAGACGGCATACGAGATATTCCGGTGACTGGAGTTCAGACGTGT

CGGAAT

CAAGCAGAAGACGGCATACGAGATAGCTAGGTGACTGGAGTTCAGACGTGT

CTAGCT

CAAGCAGAAGACGGCATACGAGATGTATAGGTGACTGGAGTTCAGACGTGT

CTATAC

CAAGCAGAAGACGGCATACGAGATTCTGAGGTGACTGGAGTTCAGACGTGT

CTCAGA

CAAGCAGAAGACGGCATACGAGATGTCGTCGTGACTGGAGTTCAGACGTGT

GACGAC

CAAGCAGAAGACGGCATACGAGATCGATTAGTGACTGGAGTTCAGACGTGT

TAATCG

CAAGCAGAAGACGGCATACGAGATGCTGTAGTGACTGGAGTTCAGACGTGT

TACAGC

CAAGCAGAAGACGGCATACGAGATATTATAGTGACTGGAGTTCAGACGTGT

TATAAT

CAAGCAGAAGACGGCATACGAGATGAATGAGTGACTGGAGTTCAGACGTGT

TCATTC

CAAGCAGAAGACGGCATACGAGATTCGGGAGTGACTGGAGTTCAGACGTGT

TCCCGA

CAAGCAGAAGACGGCATACGAGATCTTCGAGTGACTGGAGTTCAGACGTGT

TCGAAG

CAAGCAGAAGACGGCATACGAGATTGCCGAGTGACTGGAGTTCAGACGTGT

TCGGCA
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CHAPTER 5 – Discussion and future directions

106	
  
	
  

Overview
Human islet transplantation is effective in restoring normal glycemic control in type 1
diabetics (Rickels et al. 2013). However, this treatment is limited in its implementation due to
insufficient number of organ-donors. Since the primary deficit in diabetes is β-cell dysfunction,
the research community is invested in finding alternative sources of β-cells for replacement
therapy. One such strategy is to induce proliferation of pre-existing β-cells. This would expand
the number of β-cells available for transplantation in the case of type 1 diabetes, and perhaps
provide an opportunity to expand endogenous β-cell populations in type 2 diabetes. The key
hurdle in inducing β-cell proliferation is that these cells lose the ability to proliferate with age.
Deceased organ donors are usually adults, and type 2 diabetes is an age-related disorder,
meaning the target cell population is one that is inherently least likely to respond to mitogenic
stimuli.
I hypothesized that there are epigenetic underpinnings to the age-related decline in
proliferative capacity, and that targeted epigenetic modifications in adult β-cells might restore
their proliferative response. To address this hypothesis, I constructed transcriptome and DNA
methylome profiles for the β-cell across the human lifespan. I also developed a novel tool for
targeting DNA methylation to specific loci, using TALE-DNMT fusion proteins. As my first target I
chose the cell cycle inhibitor, p16, encoded by the CDKN2A locus, a well-established mediator of
age-related decline in proliferative capacity in rodent models.

I successfully increased the

proliferative capacity of primary human fibroblasts, suggesting that this epigenetic targeting
approach may be a viable tool for stimulating replication in human β-cells. Simultaneously, I
addressed a major need in the DNA methylation research field for an efficient and cost-effective
2

method for targeted bisulfite sequencing, termed BisPCR . With the appropriate datasets and
tools in place, future directions of this work will be focused on implementing targeted epigenetic
modifications in adult human β-cells.

While the foundation for such experiments has been

established, key challenges must be addressed regarding target identification and delivery of
targeted epigenetic modifiers to human β-cells.
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Addressing challenges in target identification
Analyzing genome wide data sets
I profiled the landscape of the aging β-cell by assessing gene expression across the
human life span from three months to 64 years of age. Previous aging analyses have assessed a
subset of candidate regulators, often by immunohistochemical methods from autopsy specimens.
I built RNA-Seq datasets for 23 sorted human β-cell samples so that we can begin to understand
the dynamics of gene activation for mitogenic sensors, downstream signaling molecules, and cell
cycle regulators as a function of age. This dataset is the first of its kind in the number of human
β-cell samples and the wide range of ages analyzed. For a subset of eight of these donors I also
sequenced the entire β-cell DNA methylome at single base resolution to assess the contribution
of DNA methylation to the aging process.

While these datasets undoubtedly represent a

significant contribution to the limited knowledgebase of the human β-cell, challenges in analyzing
them have stunted my ability to identify novel targets to be used in interventions.
To analyze gene expression data, I sought to conduct a time course analysis in an effort
to capture dynamic changes in gene expression that may occur across the human lifespan.
Greater statistical power could be achieved by grouping samples into “young” and “old”
categories, but the appropriate cutoff for a two state comparison is unknown. The importance of
defining an appropriate cutoff is highlighted by my observation that the 18-year old DNA
methylome showed an intermediate pattern compared to samples on either age extreme (Figure
2.2D).

If DNA methylation is in fact correlated with gene expression in an age-dependent

manner, then including these intermediate samples in either group might dilute important
differences, or make it difficult to draw correlations between gene expression and DNA
methylation. While multiple time course analysis tools are available, none are particularly suitable
to our dataset due to the lack of biological replicates at each time-point. In attempt to overcome
this challenge, we conducted linear and log-linear regression analyses of normalized read values.
While the presence of CDKN2A as a top hit provided a degree of confidence, this particular
approach is in no way comprehensive and therefore of limited utility. In the future, we plan to
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incorporate several additional types of regression analyses, or build a more customized platform
for identifying common gene expression patterns with age.

Incorporation of single-cell transcriptome and proteomic analyses
Peak proliferation of human β-cells in the postnatal period has been suggested to be
approximately 2%, and this measurement was determined by the cell cycle marker Ki67, which is
present during all active phases of the cell cycle, but not in G0 (Gregg et al. 2012; Scholzen and
Gerdes 2000).

Ki67 is not a precise measure of productive cellular replication, meaning the

percentage of cells completing mitosis may be even smaller.

Thus, in harvesting β-cell

populations, the true cells of interest are diluted amongst a large number of cells that are
potentially not of interest. In using this type of bulk assay, we are making an assumption that all
β-cells within a single donor behave in a similar manner, such that all β-cells from younger donors
are poised to replicate, while those from older donors are not. While one study has suggested
that in mice all β-cells are of equal capacity to proliferate, it is also possible that only certain
subpopulations of β-cells are poised to replicate, which would be difficult to discern, for example,
if only 2 in 100 cells fit into this category (Brennand et al. 2007).

Single-cell experiments could

provide a level of granularity that is not achieved in our bulk assays. Therefore, we are pursuing
both gene expression and proteomic single cell analyses.
The goal of single cell transcriptome analysis is to distinguish the gene expression profile
of proliferating β-cells and non-proliferating β-cells. Towards this goal, other lab members are
currently building RNA-Seq datasets for individual islet cells from young and old donors using the
Fluidigm C1 system for single cell cDNA preparation. In this system, a single cell suspension is
passed through a cartridge that captures individual cells into distinct wells, which serve as
isolated sites for cDNA preparation. RNA-Seq libraries are prepared and sequenced externally to
the C1 system.

Proliferating cells are identified by very high Ki67 mRNA expression.

transcriptome of Ki67+

High

proliferating β-cells can then be compared to that of the Ki67+

within the same sample.
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β-cells

Another interesting application of this technology is investigating human endocrine cell
subtypes. Our fluorescence-activated cell sorting procedure utilizes cell surface antibodies that
enrich for different islet cell populations, and we often assess purity by qPCR for endocrine
hormone gene expression. Preliminary single cell experiments have identified cells that express
more than one of the classic endocrine hormones, such as insulin, glucagon and somatostatin,
which has also been previously reported

(White et al. 2013).

It might be interesting to

investigate how proliferation is correlated with β-cell subtypes, as assessed by endocrine
hormone expression. Single cell transcriptome data serve as a good complement, but not a
replacement, to bulk assays, especially because the C1 system currently processes only 96 cells
at a time, and with a proliferation rate of 2% it can be challenging to capture a sufficient number
of proliferating cells. Further, the cell capture system is based on cell size, and so differences in
cell size between proliferating and quiescent cells could bias selection.
Other lab members are also currently developing a single-cell proteomic approach to
complement our genome-wide datasets.

Analyzing gene expression on the protein level is

essential because transcription can be regulated independently from translation. For instance,
even though we commonly observe glucagon mRNA in gene expression data, glucagon is not
detected at the protein level in β-cells (unpublished).

Cytometry by time-of-flight mass

spectrometry (CyTOF) is a novel single-cell mass spectrometric technique (Newell et al. 2012).
In this procedure, heavy metals isotopes are conjugated to antibodies and cells are then analyzed
by mass spectrometry. The key advantages of this procedure over traditional FACS analysis is a
higher degree of sensitivity by avoiding spectral overlap associated with FACS, and also a larger
number of channels. One important limitation is decreased cell sampling efficiency, which we
have found to be approximately 10% in comparison to >95% for FACS analysis. Our lab is
currently profiling β-cells from young and old islet donors by CyTOF.
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DYRK1A as a target for epigenetic editing
Our strategy of profiling the aging β-cell transcriptome and methylome is an example of a
“bottom-up” search for targets for inducing adult β-cell proliferation. Other groups have pursued
“top-down” approaches using high-throughput chemical screens to identify small molecules that
induce β-cell proliferation (Wang et al. 2015a; Wang et al. 2015b).

Such screens are usually

performed with libraries of thousands of chemicals, many of which have been studied in vivo, and
even in humans.

Further, since the readout is markers of proliferation as opposed to next

generation high-throughput sequencing, chemical screens are more efficient and cost-effective
than our “bottom-up” approach. However, the disadvantages to this approach are that often
times the mechanism by which a drug works is unknown, or the drug may have unacceptable offtarget effects.
A recent study by Wang and colleagues offers an interesting opportunity to combine our
targeted epigenetic editing approach with findings from a chemical screen (Wang et al. 2015b).
This screen identified harmine as a potent inducer of β-cell proliferation, which appeared to be
mediated by inhibition of dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A).
DYRK1A has been implicated in suppressing β-cell replication by inhibiting the nuclear factor of
activated T-cells (NFAT) pathway (Shen et al. 2015).

Despite this exciting finding, due to off-

target effects, harmine cannot be used clinically. Although DYRK1A expression does not appear
to increase with age in human β-cells based on our data, epigenetic suppression with TALEDNMTs could be a way to leverage the findings from this chemical screen. TALE-DNMTs can be
applied as a tool for correcting aberrant changes to the DNA methylome, or more simply as a tool
for stable transcriptional suppression. Thus, we are currently pursing DYRK1A TALE-DNMTs as
a future direction to affect β-cell replication. In summary, future efforts in target identification will
be directed towards developing a robust pipeline for analysis of genome-wide gene expression
data, incorporating single-cell analysis to corroborate our bulk assays, and exploring targets
identified through other approaches.
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Addressing challenges in TALE-DNMT delivery to the human β-cell
Improved TALE-DNMT lentiviral constructs
Our primary target for epigenetic editing with TALE-DNMTs is p16, due to its wellestablished role in mediating the age-dependent decline in proliferative capacity in murine models
(Krishnamurthy et al. 2006).

Further, our RNA-Seq data show a dramatic increase in CDKN2A

expression with age in human β-cells (Figure 2.5A). For the p16 TALE-DNMT validation study in
primary human fibroblasts, the CDKN2A promoter was selected for targeted DNA methylation,
and we saw a robust decrease in expression of the p16 transcript.

The CDKN2A promoter

contains a CpG island and is epigenetically regulated, suggesting this locus is a reasonable
TALE-DNMT target (Popov and Gil 2010).

While this region is not differentially methylated in

young and old human β-cells based on our DNA methylome data, it is still a viable strategy for
decreasing p16 levels. We will continue to pursue these specific TALE constructs, and also more
distal putative regulatory elements associated with CDKN2A that were differentially methylated in
young and old β-cells (Figure 5.1).
Our efforts in pursuing targeted epigenetic modifications in human β-cells have been
hampered by the challenges of working with this cell type in vitro. Lack of a suitable human β-cell
line in addition to the limitations of culturing primary human islets ex vivo has thus far prevented
proof of concept studies in β-cells. The differences outlined between rodent and human β-cell
proliferation suggest that it is critical to test our strategy specifically in human cells. In attempt to
overcome these limitations, we have used a xenotransplantation model by transplanting human
islets under the kidney capsule of non-obese diabetic (NOD) severe combined immunodeficiency
(SCID) mice, in which diabetes is induced by low dose streptozotocin (STZ) treatment (Levitt et
al. 2011).

Prior to transplantation, islets are infected with a lentivirus containing the p16 TALE-

DNMT transgene. We selected lentivirus as the delivery method for TALE-DNMTs because it is a
well-established technique for stably introducing transgenes into primary human cells. However,
this model is subject to its own set of challenges, including poor islet transduction efficiency. Due
to the spheroid structure of the islet, cells on the periphery are more accessible than cells towards
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the core of the islet, which are inaccessible and therefore poorly transduced. Further, due to the
loss of the vasculature during islet isolation and culture, the core often becomes necrotic. Future
efforts in TALE-DNMT delivery will be directed towards optimizing lentivirus transduction and
exploring alternative delivery methods.
We initially modified our TALE-DNMT construct to accommodate lentivirus technology by
minimizing direct repeats, or TALE jumbling, to prevent recombination during integration into the
genome. We also had to decrease the size of the TALE repeat domain and eliminate the 2A GFP
to accommodate constraints on the size of the lentivirus genome. Given the known limitations of
lentivirus transduction efficiency in human islets, we recognized the importance of assessing
proliferation specifically in transduced β-cells. We planned to detect infected cells using the Cterminal Flag-tag, which was previously used to detect the fusion protein by western blot
(Bernstein et al. 2015b).

However, we were not successful in detecting this epitope by

immunofluorescence or fluorescence-activated cell sorting (FACS) analysis. This failure could be
due to the positioning of the Flag epitope in the three-dimensional conformation of the TALEDNMT, since the western blot procedure detects the SDS-denatured protein as opposed to the
native version.
Since our lab has employed lentivirus to successfully transduce human islets in the past,
we decided to amend the constructs to improve detection. The first modification we made was to
move the Flag-tag to the N-terminus, as changing the location of the epitope could alter its
exposure for antibody detection. Despite known restrictions of the lentiviral genome size, we
decided to add back the GFP gene, since in our previous work we had isolated transfected cells
from non-transfected cells by GFP FACS sorting.
Another potential opportunity to improve our TALE-DNMT constructs is to increase
specificity, perhaps by attenuating the DNMT catalytic activity. In our study of TALE-DNMTs in
fibroblasts, we found that while the strongest changes in DNA methylation occurred at the TALE
binding site, there were distance-related changes in DNA methylation, which we termed “neartarget” effects. Conceptually, if the catalytic activity is weaker, then DNA methylation might be

113	
  
	
  

more likely to occur only where the enzyme is localized, in this case the p16 promoter. Originally,
the catalytic domain present in our fusion protein consisted of DNMT3a fused to DNMT3L. The
DNMT3L subunit does not have inherent catalytic activity, but rather enhances the activity of
DNMT3a. We hypothesize that removing the DNMT3L domain will attenuate the catalytic activity
of DNMT3a to allow local effects on DNA methylation while limiting near-target effects. Removing
the DNMT3L domain would also accommodate the addition of GFP to keep the construct within
the recommended lentiviral genome size. Thus, we modified the TALE-DNMT backbone with the
N-terminal Flag-tag such that DNMT3L and GFP were each flanked by restriction enzymes for
convenient removal as necessary. We prepared new N-flag TALE-DNMT GFP lentiviruses, with
and without DNMT3L, and a wild-type and mutant version for both constructs. Testing these
lentiviruses is a critical next step in moving TALE-DNMTs forward into human islets.
Another potential future modification to TALE expression constructs is replacing the CMV
promoter with a β-cell specific promoter, such as that of the insulin gene. In order to move closer
to clinical applications, it is important for TALE-DNMTs to have a targeted impact on
transcriptional regulation, which includes targeting the correct cell type. This two-step procedure
of validating TALE-DNMT functionality with one virus in fibroblasts and implementing a different
virus in human islets is highly inefficient. Improving transduction efficiency may permit direct in
vitro validation experiments in human islets to assess TALE-DNMTs for changes in DNA
methylation and gene expression.

Optimizing lentiviral transduction efficiency
In addition to improving lentiviral constructs to permit detection and limit “near-target”
effects, we are also pursuing efforts to optimize transduction efficiency. One approach is “islet reaggregation”, which entails enzymatic dispersion of islets followed by lentivirus infection and reaggregation of the endocrine cell suspension by orbital shaking. While this method results in very
high transduction efficiency, it also disrupts the three dimensional structure of the islet and any
intercellular connections, which may be important in paracrine signaling (Tamaki et al. 2014;
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Caicedo 2013; Barker et al. 2013).

Further, in our experience, individual re-aggregated islets

must be cultured in single wells of 12-well plates to prevent islets from clumping together, while
providing sufficient surface area for orbital shaking. Usually, we utilize a minimum of 100 islets
per mouse in a xenotransplantation experiment, making it somewhat impractical to culture
individual islets for multiple animals.

Another potential strategy for increasing transduction

efficiency is “islet loosening,” either by enzymatic or chemical disruption. While such procedures
have reported transduction efficiencies around 80%, we have not yet optimized the balance
between sufficient loosening and maintaining islet integrity (Maria Jimenez-Moreno et al. 2015).
Thus, there are a number of avenues each with several variables that can be modified towards
optimizing transduction efficiency.

Alternative TALE-DNMT delivery strategies
In the case of targeted epigenetic modifiers, genomic integration may not be necessary if
a stable epigenetic mark is incorporated.

In fact, from a therapeutic standpoint, transient

expression and a long-term effect may even be preferable. Thus, we are considering non-viral
delivery systems for transient transgene expression.

Two such alternatives include modified

RNAs (modRNAs) and electroporation. modRNAs are synthetic mRNA molecules generated by
in vitro transcription with modified cytidine and uridine ribonucleoside bases in addition to
phosphatase treatment in order to reduce cellular toxicity associated with mRNA transfection.
These synthetic molecules have been successfully used to generate induced pluripotent stem
cells (iPSCs), and then to re-differentiate these iPSCs cells to different cell fates (Warren et al.
2010).

modRNAs have also been used in vivo in a mouse model of myocardial infarction to

promote expansion and directed differentiation of endogenous heart progenitors (Zangi et al.
2013). TALE-DNMT modRNAs could be delivered to human islets in vitro to transiently express
these constructs. Further, Tamaki and colleagues used an optimized electroporation protocol to
deliver multiple siRNA to human islets and found robust suppression of several but not all target
genes, while maintaining islet structure, function and viability
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(Tamaki et al. 2014).

Electroporation could be used to deliver plasmid DNA, although delivery of modRNAs directly
would likely promote greater efficiency in generating TALE proteins.

Future utility of BisPCR2
In our genome-wide assessment of DNA methylation in the aging human β-cell, we sought to
determine the entire landscape of DNA methylation in young and old β-cells. This landscape
provides a solid foundation for understanding the function of DNA methylation globally, and for
integrating other genome-wide datasets to deepen our understanding of how DNA methylation fits
in with other mechanisms of epigenetic regulation.

While in some instances such a global

perspective is necessary, other scientific questions require surveying DNA methylation in a
targeted fashion at selected regions across many biological samples. For instance, once we
identify candidate differentially methylated regions (DMRs), we will likely need to validate findings
in a larger set of samples. The most common methods for targeted DNA methylation analysis are
fluorescence-based assays such as pyrosequencing that detect the relative amount of cytosine
residues compared to thymidine residues following bisulfite conversion. With sodium bisulfite
treatment, unmethylated cytosines are converted to uracils while methylated cytosines are
protected. Such fluorescence-based assays are limited by the number of samples that can be
processed at once, the number of CpGs that can be assessed in a single assay, and the
dependence on a secondary fluorescence enzymatic reaction. An alternative to these assays is
bisulfite conversion followed by next-generation sequencing (NGS), which leverages sample
barcoding and direct sequencing of base content in an entire DNA fragment, improving upon the
limitations listed above.
The rate-limiting step of NGS is DNA sequencing library preparation, which is a low
throughput multiple day procedure. In our assessment of DNA methylation in p16 TALE-DNMT
experiments, we did leverage an automated library preparation system, but while the hands-on
bench time was low, it still required more than one day and only eight samples could be
processed at one time.

Further, we were still subject to occasional technical failures of the

116	
  
	
  

automated system. Since targeted bisulfite sequencing approaches require an initial PCR step to
enrich for regions of interest, this initial PCR step can be used to introduce partial adapter
sequences by adding overhangs to the target enrichment primers. The addition of partial adapter
2

overhangs permitted library barcoding by a second round of PCR. Thus, the BisPCR method
permits entirely PCR-based library preparation that is extremely fast, efficient and inexpensive.
In addition to our validation study of type 2 diabetes CpG risk loci in human islets,
2

BisPCR has gained momentum in several other areas both at the University of Pennsylvania and
elsewhere. Ongoing collaborations include validation of findings from genome-wide studies in
population epigenetics, candidate gene approaches in transgenerational epigenetic inheritance,
and candidate gene approaches in cancer studies.

One could also envision the clinical

application of this technology in measuring DNA methylation for diagnostic purposes. Further,
2

others have adapted the BisPCR technology to non-DNA methylation studies such as circular
chromosome conformation capture (4C), which utilizes the PCR-based library preparation
procedure without the bisulfite conversion step. Thus, this simplified DNA sequencing library
technique has extended far beyond our initial study.
2

An opportunity for improvement upon the BisPCR technique is to make it even more
high-throughput. Despite the undisputed advantages over traditional NGS approaches, hands-on
time is still required for PCR amplification of each region of interest, pooling and purification of
samples prior to barcoding, and a final purification step for each library. Each of these steps is
relatively simple, but may become tedious when working with large sample sizes or large
numbers of target regions. One possibility to improve efficiency is to automate some of these
steps using robotic instruments that are already being implemented in our lab. The easiest steps
to automate are PCR set-up and PCR product pooling.

Automation would also reduce the
2

chances of human error when working with large sample sizes. In summary, BisPCR is an
extremely useful improvement in targeted bisulfite NGS, and beyond, and can be further
improved to increase utility.
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Future Perspectives on human β-cell rejuvenation
β-cell rejuvenation has the potential to impact type 1 diabetes in the context of pancreatic
islet transplantation, and type 2 diabetes in the context of expanding residual β-cell mass. In the
near term, β-cell rejuvenation in the transplant setting is a more realistic opportunity, since islets
can be treated ex vivo, thereby circumventing challenges with endogenous drug delivery, such as
drug safety and metabolism. There are several hurdles remaining in the islet transplantation field,
and the one investigated in the present work is the lack of sufficient donors to meet
transplantation demand. An appealing strategy for increasing donor supply is to promote β-cell
replication in human islets isolated from deceased donors ex vivo before transplantation. By
working with the native β-cell, there is a greater likelihood of maintaining cellular identity. This is
an ongoing challenge in other β-cell replacement strategies such as differentiation from stem cell
populations or transdifferentiation from other cell types. Additionally, this strategy preserves the
intricate three-dimensional structure of the human islet, which mediates paracrine interactions
between cells and promotes interactions with the microvasculature, which is critical for hormone
secretion (Menger et al. 2001).

Islet transplantation is a robust therapy for diabetes because,

unlike pharmaceutical interventions, the β-cell can respond to dynamic changes in blood glucose
levels. Thus, maintaining β-cell identity and islet architecture will optimize the success of this
strategy.
It is generally accepted that islet transplantation is curative in type 1 diabetes, and that
adult human β-cells can in some instances be induced to proliferate, primarily through over
expression or inhibition of certain cell cycle regulators. Thus, combining these two principles
could greatly decrease the burden of type 1 diabetes.

There are several considerations in

moving forward towards a clinical application, including achieving sufficient β-cell expansion while
preventing oncogenicity, and maintaining β-cell function, all of which can likely be addressed.
Cellular senescence and oncogenic transformation are opposite extremes of the same
pathways, and cannot be viewed in isolation. p16 models this point effectively since it is known to
be inactivated in a number of cancers, and yet we have shown that p16 transcript levels are
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extremely low in young human β-cells.

Further, oncogenic transformation and unrestricted

proliferation is not the result of a single mutagenic event, but rather the consequence of a
culmination of cellular changes (Hanahan and Weinberg 2011). Another critical point is that the
rate of proliferation in adult human β-cells is so low that a tremendous amount of oncogenic
stress would probably be required to permit tumor formation. In the case of p57 suppression in
human islets, increased proliferation was observed only with the added mitogenic stimulus of
hyperglycemia in vivo, and even then, proliferation increased by only 3-fold (to 2.71% of β-cells)
over the course of 20 days of xenotransplantation (Avrahami et al. 2015). This point leads to the
opposite concern of whether or not sufficient β-cell expansion can ever be achieved to have a
meaningful impact on the donor β-cell supply.
When dispersed from islet clusters, human β-cells can be induced to proliferate by large
magnitudes, but at the expense of β-cell identity (Efrat 2008). Attempts have been made towards
re-differentiating these cells with varying degrees of success.

However, in the p57 study,

Avrahami and colleagues demonstrated that newly formed human β-cells in fully intact islets have
normal glucose responsiveness (Avrahami et al. 2015). Perhaps inducing β-cell proliferation at a
lower rate, closer to peak rates observed physiologically, may provide a sufficient balance of
increasing β-cell mass while maintaining β-cell identity.
An outstanding question is whether or not it is required that β-cell expansion occur prior
to transplantation. Human islets do not survive for long ex vivo, and for testing our own genetic
and epigenetic manipulations, we transplant islets into NOD-SCID mice shortly after transduction
so they can become revascularized as soon as possible. Further, in the present strategy of
targeted epigenetic modifications, I have not yet investigated how these modifications are
maintained over time.

If they are indeed stable, β-cells will continue to replicate after

transplantation during the remainder of the recipient’s life. This strategy is potentially risky in the
context of clinical applicability, because recipients would be transplanted with a sub-therapeutic
number of islets under the presumption that β-cells will expand in vivo.

If β-cells do not

sufficiently expand, recipients may require additional transplantation procedures.
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In discussing expansion of availability of pancreatic islet transplantation, it is important to
note that graft survival depends upon adequate revascularization and protection from
inflammatory and adaptive immune response.

The normal human pancreas contains

approximately 1 million islets, corresponding to roughly one billion β-cells (Weir and Bonner-Weir
2013).

Further, according to the National Institute of Diabetes and Digestive and Kidney

Diseases (NIDDK), transplantation recipients often undergo two infusions of 400,000 to 500,000
islets (National Diabetes Information Clearinghouse, 2013). It has been reported that in humans,
overt type 1 diabetes does not occur until residual β-cell mass is reduced to about 10% (Klinke
2008). Thus, far more islets are being transplanted than are physiologically required to cure
diabetes. In addition, islets are subject to graft failure, often within five years of the procedure
(McCall and Shapiro 2014).

Even marginal improvements in increased β-cell proliferation, in

combination with improved graft survival, could greatly expand the availability of islet
transplantation.

Conclusion
In this work, we present novel human β-cell RNA-Seq and DNA methylome datasets so
that we may begin to understand the transcriptional changes that occur in the human β-cell with
age, and how DNA methylation might be implicated in this process. We also present a robust tool
for modifying DNA methylation at target loci to specifically alter gene expression.

We

demonstrated proof-of-concept for this technique by increasing proliferation in human fibroblasts
through epigenetic suppression of CDKN2A (p16). Finally, we present an improved method for
2

targeted bisulfite NGS, BisPCR , which allows more efficient, cost-effective and thorough
interrogation of DNA methylation at target regions.

Future efforts will be directed towards

improving the utility of each of these tools to enhance our potential for success in targeted
epigenetic editing in adult human β-cells.
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Figure 5.1. DNA is differentially methylated at the CDKN2A locus comparing young and
old human β-cells. Diagram depicting DNA methylation at the CDKN2A locus in young and old
human β-cells. Each bar in the plot for young and old groups represents percent methylation for
an individual CpG ranging from 0-100%. Differentially methylated regions (DMRs) are indicated
by blue bars beneath the CDKN2A gene illustration. The number of CpGs and change in percent
methylation is indicated beneath each DMR. Positive values indicate increases in percent DNA
methylation with age. DMRs determined as described in Chapter 2 methods.
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